

METHODS FOR THE QUANTITATION OF POLYPEPTIDES

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the priority benefit of U.S. Provisional Application Serial No. 62/617,080, filed January 12, 2018, the contents of which are incorporated herein by reference in their entirety.

SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

[0002] The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 183952028240SEQLIST.txt, date recorded: January 11, 2019, size: 29 KB).

FIELD OF THE INVENTION

[0003] The present invention provides methods for quantitating the amount of a polypeptide that comprises an antibody constant region (or portion thereof) with an engineered mutation in a sample.

BACKGROUND OF THE INVENTION

[0004] Proteins, such as antibodies, represent a growing class of therapeutics. During pre-clinical development, candidate therapeutic proteins undergo extensive analyses in animal models to assess their pharmacokinetic (PK), pharmacodynamics (PD), and toxicokinetic (TK) characteristics, to assess their safety profiles, and to determine a safe dose for first-in-man studies. During clinical development, the PK, PD, and TK characteristics of therapeutic proteins are analyzed further in human subjects. Data from studies in humans are used to evaluate the safety and efficacy of the therapeutic protein, to establish dosing schedules, and/or to adjust dosages in patient subpopulations. Accordingly, it is critical that methods for quantitating therapeutic proteins in both pre-clinical and clinical samples be reliable and sensitive.

[0005] Ligand binding assays (LBAs) have traditionally been employed for quantitation of therapeutic proteins, due to their high sensitivity, low cost, and high throughput. Despite these advantages, LBAs have limited linear dynamic range, carry a risk of cross reactivity across metabolites/analogues, and are difficult to multiplex. Moreover, developing new antibodies for use in LBAs for novel therapeutic proteins is both costly and labor-intensive.

[0006] Liquid chromatography tandem mass spectrometry (LC-MS/MS) has emerged as a promising assay platform for quantification of therapeutic proteins. LC-MS/MS assays used for bioanalysis of therapeutic proteins in pre-clinical animal studies frequently rely upon quantification of a “surrogate peptide” (*i.e.*, a peptide whose sequence is unique to the therapeutic protein and absent in the proteomes of pre-clinical species) as a proxy measure of therapeutic protein. Because many therapeutic proteins are derived from human proteins, the sequence of a surrogate peptide will likely be present in the human proteome, thus impeding accurate quantitation of the therapeutic protein in a sample obtained from a human subject.

[0007] Accordingly, there remains a need in the art for universal methods for quantification of therapeutic proteins in both pre-clinical (non-human) and clinical (human) samples. The present disclosure is directed to this and other needs.

[0008] All references cited in this application are expressly incorporated by reference herein.

BRIEF SUMMARY OF THE INVENTION

[0009] Provided is a method for quantitating an amount of a polypeptide comprising a portion of an antibody heavy chain constant region in a sample, the method comprising: (a) digesting the sample comprising the polypeptide comprising the portion of the antibody heavy chain constant region, wherein the portion of the antibody heavy chain constant region comprises an engineered mutation, and wherein digestion produces a peptide fragment derived from the antibody heavy chain constant region that is between 5 and 26 amino acids long and comprises the engineered mutation; and (b) analyzing the digested sample by mass spectrometry to determine quantity of the peptide fragment, thereby determining the quantity of the polypeptide comprising the portion of the antibody heavy chain constant region in the sample. In certain embodiments according to (or as applied to) any of the embodiments above, the peptide fragment does not comprise a methionine (M) or cysteine (C). In certain embodiments according to (or as applied to) any of the embodiments above, the peptide fragment does not comprise an asparagine (N) followed by a glycine (G) or serine (S). In certain embodiments according to (or as applied to) any of the embodiments above, the method further comprises purifying and concentrating the digested sample prior to the mass spectrometry analysis. In certain embodiments according to (or as applied to) any of the embodiments above, the digested sample is purified and concentrated via solid phase extraction (SPE). In certain embodiments according to (or as applied to) any of the embodiments above, the digested sample is purified

and concentrated via SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies).

[0010] In certain embodiments according to (or as applied to) any of the embodiments above, the sample is a whole blood sample, a serum sample, a plasma sample, or a tissue sample. In certain embodiments according to (or as applied to) any of the embodiments above, the sample is from a mouse, a non-human primate, or a human. In certain embodiments according to (or as applied to) any of the embodiments above, the non-human primate is a cynomolgus monkey or a rhesus monkey. In certain embodiments according to (or as applied to) any of the embodiments above, the sample is digested with at least one enzyme. In certain embodiments according to (or as applied to) any of the embodiments above, the at least one enzyme is trypsin, chymotrypsin, glutamyl endopeptidase, lysyl endopeptidase, Asp-N, Arg-C, Glu-C, cyanogen bromide (CnBr), or combinations thereof. In certain embodiments according to (or as applied to) any of the embodiments above, the mass spectrometry used to determine the quantity of the polypeptide in the sample is liquid chromatography-tandem mass spectrometry analysis (LC-MS/MS).

[0011] In certain embodiments according to (or as applied to) any of the embodiments above, the polypeptide comprises a CH1 domain, and wherein the CH1 domain comprises the engineered mutation. In certain embodiments according to (or as applied to) any of the embodiments above, the polypeptide comprises a CH2 domain, and wherein the CH2 domain comprises the engineered mutation. In certain embodiments according to (or as applied to) any of the embodiments above, the polypeptide comprises a CH3 domain, and wherein the CH3 domain comprises the engineered mutation. In certain embodiments according to (or as applied to) any of the embodiments above, the engineered mutation in the CH3 domain of the antibody heavy chain constant region is T366Y, T366W, T366S, L368A, T394W, T394S, F405A, F405W, Y407T, Y407V, or Y407A. In certain embodiments according to (or as applied to) any of the embodiments above, the engineered mutation in the CH3 domain of the antibody heavy chain constant region is Y407V, and wherein the CH3 domain comprises an amino acid sequence set forth in SEQ ID NO: 6 (DGSFFLVLS). In certain embodiments according to (or as applied to) any of the embodiments above, the digestion produces a peptide fragment comprising (such as consisting of) the amino acid sequence TTPPVLDSDGSFFLVSK (SEQ ID NO: 7), DGSFFLVSKLTV (SEQ ID NO: 8), or GSFFLVSKLTV (SEQ ID NO: 9). In certain embodiments according to (or as applied to) any of the embodiments above, the sample is

digested with trypsin, and wherein the digestion produces a peptide fragment consisting of the amino acid sequence TTPVLDSDGSFFLVSK (SEQ ID NO: 7). In certain embodiments according to (or as applied to) any of the embodiments above, the sample is digested with Asp-N, and wherein the digestion produces a peptide fragment consisting of the amino acid sequence DGSFFLVSKLTV (SEQ ID NO: 8). In certain embodiments according to (or as applied to) any of the embodiments above, the sample is digested with Glu-C, and wherein the digestion produces a peptide fragment consisting of the amino acid sequence GSFFLVSKLTV (SEQ ID NO: 9). In certain embodiments according to (or as applied to) any of the embodiments above, the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4. In certain embodiments according to (or as applied to) any of the embodiments above, the engineered mutation in the CH3 domain of the antibody heavy chain constant region is N434S. In certain embodiments according to (or as applied to) any of the embodiments above, the sample is digested with Glu-C and trypsin, and wherein the digestion produces a peptide fragment consisting of the amino acid sequence ALHSHYTQK (SEQ ID NO: 11). In certain embodiments according to (or as applied to) any of the embodiments above, the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 3.

[0012] In certain embodiments according to (or as applied to) any of the embodiments above, the polypeptide comprising the portion of the antibody heavy chain constant region is an antibody, an Fc-fusion protein, or an immunoadhesin. In certain embodiments according to (or as applied to) any of the embodiments above, the polypeptide comprising the portion of the antibody heavy chain constant region is an antibody. In certain embodiments according to (or as applied to) any of the embodiments above, the antibody is a therapeutic antibody. In certain embodiments according to (or as applied to) any of the embodiments above, the antibody is a chimeric antibody, a humanized antibody, or a human antibody. In certain embodiments according to (or as applied to) any of the embodiments above, the antibody is a monospecific antibody, a bispecific antibody, a trispecific antibody, or a multispecific antibody. In certain embodiments according to (or as applied to) any of the embodiments above, the antibody is a trispecific antibody. In certain embodiments according to (or as applied to) any of the embodiments above, the trispecific antibody comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more antigen targets or target proteins, wherein a first polypeptide comprises a structure represented by the formula: VL2-L1-VL1-L2-CL; the second polypeptide chain comprises a structure represented by the formula: VH1-L3-

VH2-L4-CH1-hinge-CH2-CH3; the third polypeptide chain comprises a structure represented by the formula: VH3-CH1-hinge-CH2-CH3; the fourth polypeptide chain comprises a structure represented by the formula: VL3-CL, wherein VL1 is a first immunoglobulin light chain variable domain; VL2 is a second immunoglobulin light chain variable domain; VL3 is a third immunoglobulin light chain variable domain; VH1 is a first immunoglobulin heavy chain variable domain; VH2 is a second immunoglobulin heavy chain variable domain; VH3 is a third immunoglobulin heavy chain variable domain; CL is an immunoglobulin light chain constant domain; CH1 is an immunoglobulin CH1 heavy chain constant domain; and L1, L2, L3 and L4 are amino acid linkers; wherein the first and second polypeptides form a cross-over light chain-heavy chain pair; and wherein the second polypeptide chain or the third polypeptide chain comprises the amino acid sequence TTPPVLDSDGSFFLVSK (SEQ ID NO: 7), DGSFFLVSKLTV (SEQ ID NO: 8), or GSFFLVSKLTV (SEQ ID NO: 9). In certain embodiments according to (or as applied to) any of the embodiments above, the first polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 12; the second polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 13; the third polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 14, and the fourth polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 15.

[0013] In certain embodiments according to (or as applied to) any of the embodiments above, the antibody is conjugated to a drug or a label. In certain embodiments according to (or as applied to) any of the embodiments above, the drug is selected from a chemotherapeutic agent, a cytotoxic agent, or a growth-inhibitory agent. In certain embodiments according to (or as applied to) any of the embodiments above, the label is a radioisotope, a fluorescent dye, or an enzyme. In certain embodiments according to (or as applied to) any of the embodiments above, the antibody is a human IgG antibody. In certain embodiments according to (or as applied to) any of the embodiments above, the IgG antibody is a human IgG1 antibody or a human IgG4 antibody. In certain embodiments according to (or as applied to) any of the embodiments above, the antibody binds A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H4/VTCN1, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1b, CCL5/RANTES, CCL7/MCP-3, CCL8/mcp-2, CCL11/eotaxin, CCL15/MIP-1d, CCL17/TARC, CCL19/MIP-3b, CCL20/MIP-3a, CCL21/MIP-2, CCL24/MPIF-2/eotaxin-2, CCL25/TECK, CCL26/eotaxin-3, CCR3, CCR4, CD3, CD19, CD20, CD23/FCER2, CD24, CD27, CD28, CD38, CD39, CD40, CD70, CD80/ B7-1, CD86/B7-2,

CD122, CD137/41BB, CD137L, CD152/CTLA4, CD154/CD40L, CD160, CD272, CD273/PDL2, CD274/PDL1, CD275/B7H2, CD276/B7H3, CD278/ ICOS, CD279/PD-1, CDH1/E-cadherin, chitinase, CLEC9, CLEC91, CRTH2, CSF-1/M-CSF, CSF-2/GM-CSF, CSF-3/GCSF, CX3CL1/SCYD1, CXCL12/SDF1, CXCL13, CXCR3, DNGR-1, ectonucleoside triphosphate diphosphohydrolase 1, EGFR, ENTPD1, FCER1A, FCER1, FLAP, FOLH1, Gi24, GITR, GITRL, GM-CSF, Her2, HHLA2, HMGB1, HVEM, ICOSLG, IDO, IFN α , IgE, IGF1R, IL2Rbeta, IL1, IL1A, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL10, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb/IL25, IL18, IL22, IL23, IL25, IL27, IL33, IL35, ITGB4/b4 integrin, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, NCR3LG1, NKG2D, NTPDase-1, OX40, OX40L, PD-1H, platelet receptor, PROM1, S152, SISP1, SLC, SPG64, ST2/receptor for IL33, STEAP2, Syk kinase, TACI, TDO, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP/ IL7Ra, TSLPR, TWEAK, VEGF, VISTA, Vstm3, WUCAM, or XCR/GPR5/CCXCR1. In certain embodiments according to (or as applied to) any of the embodiments above, the method is for use in pharmacokinetic study of the polypeptide comprising an antibody heavy chain constant region in a mouse, a non-human primate, and a human.

[0014] Each embodiment herein described may be combined with any other embodiment or embodiments unless clearly indicated to the contrary. In particular, any feature or embodiment indicated as being preferred or advantageous may be combined with any other feature or features or embodiment or embodiments indicated as being preferred or advantageous, unless clearly indicated to the contrary. These and other aspects of the invention will become apparent to one of skill in the art. These and other embodiments of the invention are further described by the detailed description that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] **FIG. 1** shows sequence alignments of the Fc regions of several exemplary therapeutic antibodies. Predicted tryptic peptides that comprise at least one amino acid substitution are underlined. The cysteines present within tryptic peptides are denoted with thick arrows. SEQ ID NOs: 2 and 5 include the knob mutation T366W. SEQ ID NOs: 3 and 4 comprise the hole mutations T366S, L368A, and Y407V.

[0016] **FIGs. 2A-2C** show the results of LC-MS/MS analysis of a tryptically-digested trispecific construct (TRI-1) that comprises heavy chains with the amino acid sequences set forth in SEQ ID NOs: 2 and 3. SEQ ID NO: 2 comprises the engineered “knob” mutation T366W, and SEQ ID NO: 3 comprises engineered “hole” mutations T366S, L368A, and Y407V. Tryptic digestion of SEQ ID NO: 3 predicted to produce a peptide having the amino acid sequence TTPPVLDSDGSFFLVSK (SEQ ID NO: 7), i.e., the “engineered TTPP peptide”. **FIG. 2A** shows the extracted ion chromatogram for m/z 905.40-907.60. **FIG. 2B** shows the total ion chromatogram. **FIG. 2C** shows the MS/MS spectrum of the engineered TTPP peptide.

[0017] **FIGs. 3A-3D** show extracted ion chromatograms of tryptically-digested mouse serum (**FIG. 3A**), monkey serum (**FIG. 3B**), human serum (**FIG. 3C**), and TRI-1 in PBST (**FIG. 3D**). The runtime for engineered TTPP is denoted by a box.

[0018] **FIGs. 4A-4D** show extracted ion chromatograms of tryptically-digested TRI-1 in mouse serum (**FIG. 4A**), monkey serum (**FIG. 4B**), human serum (**FIG. 4C**), and PBST (**FIG. 4D**). The runtime for engineered TTPP is denoted by a box.

[0019] **FIGs. 5A-5C** show extracted ion chromatograms of engineered TTPP from tryptically-digested TRI-1 in PBST, m/z = 905.36-905.55. TRI-1 concentrations were 20 µg/mL (**FIG. 5A**), 2 µg/mL (**FIG. 5B**), and 0.2 µg/mL (**FIG. 5C**). The peak areas for the TTPP peptide were 44064886 (**FIG. 5A**), 2633166 (**FIG. 5B**), and 368649 (**FIG. 5C**).

[0020] **FIGs. 6A-6C** show extracted ion chromatograms of unlabeled FNWYVDGVEVHNAK (SEQ ID NO: 10) (FNWY) from tryptically-digested TRI-1 in PBST, m/z = 559.90-559.98. TRI-1 concentrations were 20 µg/mL (**FIG. 6A**), 2 µg/mL (**FIG. 6B**), and 0.2 µg/mL (**FIG. 6C**). The peak areas for the FNWY peptide were 70091279 (**FIG. 6A**), 1078300 (**FIG. 6B**), and 209110 (**FIG. 6C**).

[0021] **FIGs. 7A-7C** show extracted ion chromatograms of isotopically labeled FNWY (FNWY(Heavy)) from tryptically-digested SILUMAB used as an internal standard for TRI-1 digestion in PBST, m/z = 562.58-562.63. TRI-1 concentrations were 20 µg/mL (**FIG. 7A**), 2 µg/mL (**FIG. 7B**), and 0.2 µg/mL (**FIG. 7C**). The peak areas for the FNWY peptide were 1369078 (**FIG. 7A**), 343482 (**FIG. 7B**), and 473743 (**FIG. 7C**).

[0022] **FIGs. 8A-8D** show extracted ion chromatograms of engineered TTPP from tryptically-digested TRI-1 in mouse serum, m/z = 905.39-905.55. TRI-1 concentrations were 0 µg/mL (control) (**FIG. 8A**), 0.2 µg/mL (**FIG. 8B**), 2 µg/mL (**FIG. 8C**), and 20 µg/mL (**FIG. 8D**).

8D). The peak areas for the TTPP peptide were ND (not detected) (**FIG. 8A**), ND (not detected) (**FIG. 8B**), 2168471 (**FIG. 8C**), and 11833127 (**FIG. 8D**).

[0023] **FIGs. 9A-9D** show extracted ion chromatograms of unlabeled FNWY from tryptically-digested TRI-1 in mouse serum, $m/z = 559.90-559.98$. TRI-1 concentrations were 0 $\mu\text{g/mL}$ (control) (**FIG. 9A**), 0.2 $\mu\text{g/mL}$ (**FIG. 9B**), 2 $\mu\text{g/mL}$ (**FIG. 9C**), and 20 $\mu\text{g/mL}$ (**FIG. 9D**). The peak areas for the FNWY peptide were ND (not detected) (**FIG. 9A**), 410330 (**FIG. 9B**), 2500109 (**FIG. 9C**), and 22039621 (**FIG. 9D**).

[0024] **FIGs. 10A-10D** show extracted ion chromatograms of FNWY(Heavy) from tryptically-digested SILUMAB used as an internal standard for TRI-1 digestion in mouse serum, $m/z = 562.58-562.63$. TRI-1 concentrations were 0 $\mu\text{g/mL}$ (control) (**FIG. 10A**), 0.2 $\mu\text{g/mL}$ (**FIG. 10B**), 2 $\mu\text{g/mL}$ (**FIG. 10C**), and 20 $\mu\text{g/mL}$ (**FIG. 10D**). The peak areas for the FNWY peptide were 1184181 (**FIG. 10A**), 2310675 (**FIG. 10B**), 1199642 (**FIG. 10C**), and 967309 (**FIG. 10D**).

[0025] **FIGs. 11A-11D** show extracted ion chromatograms of engineered TTPP from tryptically-digested TRI-1 in monkey serum, $m/z = 905.39-905.55$. TRI-1 concentrations were 0 $\mu\text{g/mL}$ (control) (**FIG. 11A**), 0.2 $\mu\text{g/mL}$ (**FIG. 11B**), 2 $\mu\text{g/mL}$ (**FIG. 11C**), and 20 $\mu\text{g/mL}$ (**FIG. 11D**). The peak areas for the TTPP peptide were ND (not detected) (**FIG. 11A**), ND (not detected) (**FIG. 11B**), 1013964 (**FIG. 11C**), and 3751017 (**FIG. 11D**).

[0026] **FIGs. 12A-12D** show extracted ion chromatograms of unlabeled FNWY from tryptically-digested TRI-1 in monkey serum, $m/z = 559.92-559.95$. TRI-1 concentrations were 0 $\mu\text{g/mL}$ (control) (**FIG. 12A**), 0.2 $\mu\text{g/mL}$ (**FIG. 12B**), 2 $\mu\text{g/mL}$ (**FIG. 12C**), and 20 $\mu\text{g/mL}$ (**FIG. 12D**). The peak areas for the FNWY peptide were 75675 (**FIG. 12A**), 97731 (**FIG. 12B**), 1298150 (**FIG. 12C**), and 13378187 (**FIG. 12D**).

[0027] **FIGs. 13A-13D** show extracted ion chromatograms of FNWY (Heavy) from tryptically-digested SILUMAB used as an internal standard for TRI-1 digestion in monkey serum, $m/z = 562.58-562.63$. TRI-1 concentrations were 0 $\mu\text{g/mL}$ (control) (**FIG. 13A**), 0.2 $\mu\text{g/mL}$ (**FIG. 13B**), 2 $\mu\text{g/mL}$ (**FIG. 13C**), and 20 $\mu\text{g/mL}$ (**FIG. 13D**). The peak areas for the FNWY peptide were 1446203 (**FIG. 13A**), 1216254 (**FIG. 13B**), 1271728 (**FIG. 13C**), and 1344983 (**FIG. 13D**).

[0028] **FIGs. 14A-14D** show extracted ion chromatograms of engineered TTPP from tryptically-digested TRI-1 in human serum, $m/z = 905.39-905.55$. TRI-1 concentrations were 0

μg/mL (control) (**FIG. 14A**), 0.2 μg/mL (**FIG. 14B**), 2 μg/mL (**FIG. 14C**), and 20 μg/mL (**FIG. 14D**). The peak areas for the TTPP peptide were ND (not detected) (**FIG. 14A**), ND (not detected) (**FIG. 14B**), 194065 (**FIG. 14C**), and 1848332 (**FIG. 14D**).

[0029] **FIGs. 15A-15D** show comparisons of area ratio to antibody concentration. **FIG. 15A** shows a comparison of the area ratio of engineered TTPP: FNWY(Heavy) versus antibody concentration of TRI-1 in PBST. **FIG. 15B** shows a comparison of the area ratio of unlabeled FNWY:FNWY(Heavy) versus antibody concentration of TRI-1 in PBST. **FIG. 15C** shows a comparison of the area ratio of engineered TTPP: FNWY(Heavy) versus antibody concentration of TRI-1 in mouse serum. **FIG. 15D** shows a comparison of the area ratio of engineered TTPP:FNWY(Heavy) versus antibody concentration of TRI-1 in monkey serum.

[0030] **FIG. 16** shows the sequences of the heavy chains and light chains of the exemplary trispecific antibody quantified in Example 2. The sequences of the surrogate peptides quantified in the LC-MS/MS assay are underlined.

[0031] **FIG. 17** shows a schematic of the exemplary trispecific antibody and where the sequences of the surrogate peptides underlined in **FIG. 16** are located in the trispecific antibody.

[0032] **FIG. 18** provides an exemplary workflow diagram of a method of quantifying the trispecific antibody using the TTPP peptide.

[0033] **FIG. 19A** shows an exemplary chromatogram of the TTPP peptide at LLOQ (lowest limit of quantification, 2.5 μg/ml). **FIG. 19B** shows an exemplary chromatogram of a stable isotope-labeled TTPP peptide (standard [¹³C11-¹⁵N2]-LTTPPVLDSDGSFFLVSK (SEQ ID NO: 20), which was used as an internal standard in Example 3. **FIG. 19C** shows a calibration curve of TTPP peptide over the range of 2.5 μg/mL -10,000 μg/mL.

[0034] **FIG. 20A** shows a serum calibration curve analyzed using linear regression analysis with 1/x weighting. The **FIG. 20B** shows a second serum calibration curve analyzed using linear regression analysis with 1/x weighting. The samples used to construct the curves in **FIGs. 20A** and **20B** were obtained from separate experiments described in Example 3.

[0035] **FIG. 21A** shows a comparison of relative levels of trispecific antibody as detected by measuring levels of the TTPP peptide in serum obtained from mice to which trispecific antibody was administered via LC-MS/MS. **FIG. 21B** shows a comparison of relative levels of trispecific

antibody as detected via ELISA in serum obtained from mice to which trispecific antibody was administered.

[0036] FIG. 22A shows the results of LC-MS/MS analysis of a blank rat serum sample. FIG. 22B shows the MS/MS spectrum of a rat serum sample spiked with 5 µg/ml trispecific antibody. FIG. 22C shows the results of LC-MS/MS analysis of a blank monkey serum sample. FIG. 22D shows the MS/MS spectrum of a monkey serum sample spiked with 5 µg/ml trispecific antibody. FIG. 22E shows the results of LC-MS/MS analysis of a blank monkey serum sample. FIG. 22F shows the MS/MS spectrum of a human serum sample spiked with 5 µg/ml trispecific antibody.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0037] As used herein, an “antibody constant region” refers to the more conserved region of the antibody, *e.g.*, outside the variable domains. The term may include the light chain constant region, *i.e.*, the CL domain, the hinge region, as well as heavy chain constant domains CH1, CH2, CH3 and, optionally, CH4.

[0038] As used herein, the term “engineered mutation” refers to a mutation created by human design (*i.e.*, the mutation did not spontaneously occur by natural causes and/or was the result of intentional human manipulation).

[0039] As used herein, the term “antibody” may refer to intact antibodies, antibody fragments comprising at least a portion of a heavy chain constant region (including, without limitation, Fab, F(ab')₂, Fab'-SH, Fv, scFv, or single heavy chain antibodies), provided that they exhibit the desired biological activity; monoclonal antibodies; polyclonal antibodies; monospecific antibodies; multi-specific antibodies (*e.g.*, bispecific antibodies and trispecific antibodies); and antibody-like proteins.

[0040] The term “antibody” typically refers to heterotetrameric complexes including two light (L) chains and two heavy (H) chains. Variable numbers of disulfide bonds connect the two heavy chains, and one connects each light chain to a heavy chain, in addition to intrachain disulfide bridges. The heavy chains include a variable domain (VH) followed (N-terminus to C-terminus) by three or four constant domains. The light chains include a variable domain (VL)

followed by a constant domain (CL). Typically, mammalian light chains fall into one of two categories based on amino acid sequence: kappa and lambda.

[0041] As used herein, the term “multispecific” when used in reference to an antibody or antibody fragment includes an antibody or antibody fragment that possesses two or more different binding specificities (e.g., bispecific and trispecific antibodies). For example, each binding specificity may recognize a different antigen, or each binding specificity may recognize the same antigen with different affinity and/or precise epitope. In some embodiments, each different binding specificity comprises one or more different antibody antigen binding domains (e.g., variable domains), such that the multispecific antibody or antibody fragment comprises, e.g., a first antigen binding domain with a first binding specificity, a second antigen binding domain with a second binding specificity, etc. A variety of exemplary multispecific antibody formats (e.g., bispecific and trispecific antibody formats) are known in the art and described in further detail elsewhere herein.

[0042] Before describing the disclosed embodiments in detail, it is to be understood that the present disclosure is not limited to particular compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0043] As used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a molecule” optionally includes a combination of two or more such molecules, and the like.

[0044] As used herein, the term “about” refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.

[0045] It is understood that aspects and embodiments of the present disclosure include “comprising,” “consisting,” and “consisting essentially of” aspects and embodiments.

Methods for Quantitating a Polypeptide in a Sample

[0046] Mass spectrometry (MS) is a feasible alternative to ligand-binding assays (LBAs) for the quantitative analysis of therapeutic proteins in samples obtained from, e.g., pre-clinical

animal studies. The typical procedure for MS-based quantification entails digesting each sample to generate peptide fragments and quantifying the amount of a specific peptide derived from the therapeutic protein as a surrogate for the therapeutic protein itself. Currently, “universal” surrogate peptides derived from the constant region of a human antibody are being used in generic methods for the quantification of human, humanized, or chimeric antibodies in nonhuman animal models. Such generic methods are based on the principle that the sequence of the “universal” surrogate peptide is conserved throughout all human Fc domains, but is absent from species in which preclinical efficacy and safety studies are performed (e.g., mice, rats, dogs, monkeys, etc.). However, it is not possible to use “universal” surrogate peptides to accurately quantitate, e.g., a therapeutic protein comprising a constant region of human antibody, in samples from human patients, as the sequence of the “universal” surrogate peptide is also present in endogenous human antibodies.

[0047] Many therapeutic proteins (e.g., antibodies) that comprise a constant region of human antibody also comprise engineered mutations that have been introduced into the constant region in order to, e.g., modulate effector function, modulate serum half-life, promote heterodimerization, etc. Applicants found that peptides derived from the portion of the constant region that contains an engineered mutation are unique in both non-human and human proteome backgrounds. Accordingly, the methods described herein may be used to quantitate therapeutic proteins in both preclinical samples (i.e., obtained from animal species) and clinical samples (i.e., obtained from human patients).

[0048] Provided are methods for quantitating an amount of a polypeptide in a sample, wherein the polypeptide comprises a portion of an antibody heavy chain constant region, and wherein the portion of the antibody heavy chain constant region comprises with an engineered mutation. In some embodiments, the method comprises the steps of: (a) digesting a sample that is suspected of comprising the polypeptide to produce a digested sample comprising a peptide fragment that comprises the engineered mutation; and (b) analyzing the digested sample via mass spectrometry to determine a quantity of the peptide fragment that comprises the engineered mutation, thereby determining the quantity of the polypeptide. Polypeptides that may be quantified using the methods described herein (e.g., fusion proteins, immunoadhesins, and antibodies) are described in further detail elsewhere herein.

[0049] In some embodiments, the methods provided herein are used in pharmacokinetic studies (such as in preclinical research or in a clinical trial). In some embodiments, the methods comprise the step of administering the polypeptide that comprises a portion of antibody heavy chain constant region with an engineered mutation to an animal, e.g., during pre-clinical research, prior to quantification. Exemplary non-human animals to which the polypeptide that comprises a portion of antibody heavy chain constant region with an engineered mutation may be administered are described in detail below. In some embodiments, the methods comprise administering the polypeptide that comprises a portion of antibody heavy chain constant region with an engineered mutation to a human, e.g., a human patient during a clinical trial, prior to quantification.

[0050] In some embodiments, the sample comprising the polypeptide that comprises a portion of antibody heavy chain constant region with an engineered mutation is a biological sample that is derived, obtained, or separated from an animal. In some embodiments, the animal from which the sample is derived, obtained, or separated is an animal to which the polypeptide that comprises a portion of antibody heavy chain constant region with an engineered mutation was administered. In some embodiments, the animal is a mammal. In some embodiments, the mammal is a human (e.g., a human patient), a non-human primate (NHP) (e.g., a cynomolgus monkey, a rhesus monkey, a marmoset, a tamarin, a spider monkey, an owl monkey, a squirrel monkey, a vervet monkey, a baboon, or others), or a rodent (e.g., a mouse or rat).

[0051] In some embodiments, the sample to be analyzed according to a method provided herein is any sample that is suspected to contain the polypeptide that comprises a portion of an antibody heavy chain constant region with an engineered mutation. In some embodiments, the sample is or is derived from a bodily fluid, including, but not limited to, e.g., blood, plasma, serum, milk, bronchial lavage, amniotic fluid, saliva, bile, or tears. In some embodiments, the sample comprises tissue or cells. In some embodiments, the sample comprises serum and a known quantity of the peptide (i.e., “spiked” serum). In some embodiments, the spiked serum further comprises a buffer. In some embodiments, the spiked serum serves as a reference for quantifying the amount of the polypeptide comprising a portion of an antibody heavy chain constant region with an engineered mutation present in a sample derived, obtained, or separated from an animal.

[0052] In some embodiments, the method further comprises treating the sample prior to digestion in order to, *e.g.*, enrich the polypeptide that comprises a portion of an antibody heavy chain constant region with an engineered mutation in the sample, or to, *e.g.*, deplete abundant proteins from a sample (such as albumin from a blood, serum, or plasma sample). In some embodiments, treating the sample comprises performing an antibody pull-down assay. Alternatively or additionally, in some embodiments, treating the sample comprises performing gel electrophoresis, extraction, precipitation, centrifugation, chromatography (*e.g.*, affinity capture chromatography, size exclusion chromatography, etc.), ultrafiltration, and/or one or more additional separation steps known to those of ordinary skill in the art.

[0053] In some embodiments, the sample is digested via chemical cleavage. Exemplary chemical reagents that cleave at specific sites in polypeptides include, but are not limited to, *e.g.*, formic acid, hydroxylamine, iodosobenzoic acid, and NTCB (2-nitro-5-thiocyanobenzoic acid). In some embodiments, the sample is digested with an enzyme, *e.g.*, an endopeptidase. In some embodiments, the enzyme is a site-specific endopeptidase. Exemplary site-specific proteases include, but are not limited to, trypsin, chymotrypsin (high specificity, cleaves c-terminal to FYW, not before P), chymotrypsin (low specificity, cleaves c-terminal to FYWML, not before P), glutamyl endopeptidase, lysyl endopeptidase, Asp-N protease, Arg-C protease, Lys-C protease, Lys-N protease, *Staphylococcus aureus* V8 (also known as glutamyl endopeptidase or Glu-C protease), cyanogen bromide (CnBr), elastase, pepsin (pH = 1.3), pepsin (pH > 2), neprilysin, BNPS-skatole, caspase 1, caspase 2, caspase 3, caspase 4, caspase 5, caspase 6, caspase 7, caspase 8, caspase 9, caspase 10, clostripain, enteroinase, Factor Xa, Granzyme B, thermolysin, proline-endopeptidase, *Staphylococcus* peptidase I, thrombin, and Tobacco etch virus protease. In some embodiments, the sample is digested with a non-specific endopeptidase, *e.g.*, papain or proteinase K. In some embodiments, the sample is digested with a mixture comprising two (or more) endopeptidases (including site-specific and/or non-site-specific). In some embodiments, the two or more endopeptidases are used simultaneously to digest the sample. In some embodiments, the two or more endopeptidases are used sequentially to digest the sample. Methods for digesting polypeptides in preparation for analysis via mass spectrometry are well known in the art. Exemplary methods are provided in, *e.g.*, Gundry *et al.* (2009) *Curr Protoc Mol Biol.* doi: 10.1002/0471142727.mb1025s88; Hedrick *et al.* (2015) *Curr Protoc Chem Biol.* 7(3): 201-222; Giansanti *et al.* (2016) *Nature Protocols.* 11: 993-1006;

Nordhoff et al. (Int J Mass Spect. 226(1): 163-180; and Zhang et al. (2014) *Curr Protoc Mol Biol.* doi: 10.1002/0471142727.mb1021s108.

[0054] Digestion of the sample produces a peptide fragment that comprises the engineered mutation. In some embodiments the peptide fragment produced by the digestion is between 5 and 40 amino acids in length, *e.g.* 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 amino acids in length. In some embodiments, the peptide fragment does not comprise cysteine (Cys) and/or methionine (M) residues. Alternatively or additionally, in some embodiments, the peptide does not comprise an asparagine residue (N) followed by a glycine residue (G) or a serine residue (S) (*i.e.*, NG or NS). In some embodiments, the peptide fragment does not comprise adjacent endopeptidase cleavage sites, *e.g.*, two or more site-specific endopeptidase cleavage sites separated by 6, 5, 4, 3, 2, or 1 amino acids. A variety of *in silico* tools have been developed to predict the peptide populations that can be produced via digestion (*e.g.*, digestion with a single enzyme or chemical cleavage reagent or a digestion with a combination of enzymes and/or chemical cleavage reagents). Such tools, which include (without limitation) PChopper, PeptideCutter, MAPPP, IPEP, MS-Digest, and Protein Digestion Simulator, are well known in the art and are publicly available, such as on the World Wide Web.

[0055] In some embodiments, the method further comprises purifying and/or concentrating the digested sample prior to analysis via mass spectrometry. In some embodiments, purifying and/or concentrating the digested sample comprises performing an affinity capture chromatography or a solid-phase extraction (SPE), and eluting a purified and concentrated sample. (*See, e.g.*, Gudry et al. (2009) "Preparation of Proteins and Peptides for Mass Spectrometry Analysis in a Bottom-Up Proteomics Workflow." *Curr Protoc Mol Biol.* CHAPTER: Unit10.25. doi:10.1002/0471142727.mb1025s88.) In some embodiments, purifying and/or concentrating the digested sample comprises performing a Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). In some embodiments, the sample is subjected to an antibody pull-down assay, digested (*e.g.*, using one or more endopeptidases known in the art), and purified and/or concentrated via SISCAPA. Details regarding SISCAPA are provided in, *e.g.*, Anderson *et al.* (2004) "Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). *J Proteome Res.* 3(2): 235-44; U.S. Patent Nos. 7,632,686 and 9,164,089; Whiteaker *et al.* (2011) "Evaluation of large scale quantitative proteomic assay

development using peptide affinity-based mass spectrometry.” *Mol Cell Proteomics*. 10(4):M110.005645; and Rasavi *et al.* (2016) “Multiplexed longitudinal measurement of protein biomarkers in DBS using an automated SISCAPA workflow.” *Bioanalysis*. 8(15):1597-1609.

[0056] In some embodiments the digested sample is analyzed via liquid chromatography-tandem mass spectrometry (LC-MS/MS). LC-MS/MS is a method where a sample mixture is first separated by liquid chromatography before being ionized (e.g., via electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), or atmospheric pressure photo-ionization (APPI)) and characterized by mass-to-charge ratio and relative abundance using two mass spectrometers in series. Details regarding LC-MS/MS are provided in, e.g., Grebe *et al.* (2011) “LC-MS/MS in the Clinical Laboratory – Where to From Here?” *Clin. Biochem Review*. 32(1): 5–31; El-Khoury *et al.* “Liquid Chromatography-Tandem Mass Spectrometry in the Clinical Laboratory.” *J. Chrom. & Separation Tech*. 4:e115. doi: 10.4172/2157-7064.1000e115; Shushan *et al.* (2010) “A review of clinical diagnostic applications of liquid chromatography–tandem mass spectrometry.” *Mass Spec. Rev*. 29:930–944, 2010.

[0057] In some embodiments, the methods provided herein can be used to detect the peptide in a sample, wherein the concentration of the peptide in the sample is any one of about 200, 150, 100, 50, 15, 10, 5, 1, 0.5, 0.25, 0.1, 0.075, 0.05, 0.025, or 0.01 ng/ml, including any range in between these values.

Engineered Mutations in an Antibody Heavy Chain Constant Region

[0058] In some embodiments, polypeptide quantitated according to a method provided herein comprises a CH1 domain (or a portion thereof, e.g., between 10 and 50 amino acids) that comprises an engineered mutation. In some embodiments, the CH1 domain extends from about residue 114 to about residue 223 of the antibody heavy chain, according to the Kabat numbering system. In some embodiments, the CH1 domain extends from about residue 118 to about residue 215 of the antibody heavy chain, according to the EU numbering system. *See, e.g.,* International Immunogenetics Information System (IMGT) Web Resources at WorldWideWeb.imgt.org/IMGTScientificChart/Numbering/Hu_IGHGnber.html. These amino acid residue positions are based on human IgG; however, it is not intended that methods provided herein be limited to use with polypeptides comprising the CH1 domain (or portion

thereof) of a human IgG. Corresponding CH1 domain sequences from other human Igs, and corresponding CH1 domain sequences of other mammals (*e.g.*, macaque, cynomolgus monkey, mouse, rat, etc.) are publicly available.

[0059] In certain embodiments, the engineered mutation in the CH1 domain (or portion thereof) comprises (such as consists of) an amino acid substitution, insertion, or deletion that does not affect (or substantially affect) the desired activity of the polypeptide comprising the antibody heavy chain constant region. In some embodiments, a substitution or insertion comprises the substitution or insertion of an unnatural amino acid or a conjugated amino acid. The amino acid substitution, insertion, or deletion can be introduced into the CH1 domain (or portion thereof) by altering the nucleic acid encoding the polypeptide (*e.g.* by site-specific mutagenesis) or by peptide synthesis, as described in further detail elsewhere herein.

[0060] In certain embodiments, the polypeptide to be quantitated according to a method provided herein comprises a human IgG1 CH1 domain (or portion thereof). In some embodiments, the engineered mutation in the human IgG1CH1 domain (or portion thereof) drives Fc heterodimerization (*e.g.*, for the production of bispecific antibodies, multispecific antibodies, or one-armed antibodies). In some embodiments, the engineered mutation in the human IgG1 CH1 domain (or portion thereof) is an amino acid substitution at K147 or K213 (according to the EU numbering system). In some embodiments, the engineered mutation in the human IgG1 CH1 domain comprises (such as consists of) the amino acid substitution K147D, K147E, K213D, or K213E (according to the EU numbering system).

[0061] In certain embodiments, the polypeptide to be quantitated according to a method provided herein comprises a CH2 domain (or a portion thereof, *e.g.*, between 10 and 50 amino acids) that comprises an engineered mutation. In some embodiments, the CH2 domain of a human IgG extends from about residue 231 to about residue 340 of the antibody heavy chain, according to the EU numbering system. *See, e.g.*, International Immunogenetics Information System (IMGT) Web Resources at WorldWideWeb.imgt.org/IMGTScientificChart/Numbering/Hu_IGHGnber.html. These amino acid positions are based on human IgG; however, is not intended that methods provided herein be limited to use with polypeptides comprising the CH2 domain (or portion thereof) of a human IgG. Corresponding CH2 domain sequences from other human Igs are publicly available, as are the corresponding CH2 domain sequences of other mammals (*e.g.*, macaque, cynomolgus

monkey, rat, mouse, etc.). In certain embodiments, the engineered mutation in the CH2 domain (or portion thereof) comprises an amino acid substitution, insertion, or deletion that does not affect (or substantially affect) the desired activity of the polypeptide comprising the antibody heavy chain constant region. In some embodiments, a substitution or insertion comprises the substitution or insertion of an unnatural amino acid or a conjugated amino acid.

[0062] In certain embodiments, the polypeptide to be quantitated according to a method provided herein comprises a human IgG1 CH2 domain (or portion thereof). In some embodiments, the engineered mutation in the human IgG1 CH2 domain (or portion thereof) modulates effector function. In some embodiments, the engineered mutation in the human IgG1 CH2 domain (or portion thereof) comprises an amino acid substitution at one (or more) of the following residues: E233, L234, L235, G236, P238, S239, F243, T250, M252, S254, T256, P257, S267, R292, Q295, N297, S298, T299, Y300, Q311, K322, A327, L328, P329, A330, P331, I332, and E333 (according to the EU numbering system). In some embodiments, the engineered mutation in the human IgG1 CH2 domain (or portion thereof) comprises one (or more) of the following amino acid substitutions: E233P, L234V, L234A, L235V, L235A,, G236A, P238D, S239D, F243L, T250Q, T250R, M252Y, S254T, T256E, P257I, S267E, R292P, Q295R, N297Q, N297D, N297A, S298G, S298N, S298C, S298A, S28T, T299A, Y300L, Q311I, K322A, A327G, L328E, L328F, L328W, P329G, P329N, A330S, A330L, A330V, P331S, P331V, I332E, I332Y, E333A, and E333S (according to the EU numbering system). Alternatively or additionally, the engineered mutation in the human IgG1 CH2 domain (or portion thereof) comprises (such as consists of) ΔG236 (according to the EU numbering system).

[0063] In certain embodiments, the polypeptide to be quantitated according to a method provided herein comprises a human IgG2 CH2 domain (or portion thereof). In some embodiments, the engineered mutation in the human IgG2 CH2 domain (or portion thereof) modulates effector function. In some embodiments, the engineered mutation in the human IgG2 CH2 domain (or portion thereof) comprises an amino acid substitution at one (or more) of the following residues: K326 and E333 (according to the EU numbering system). In some embodiments, the engineered mutation in the human IgG1 CH2 domain (or portion thereof) comprises one (or more) of the following amino acid substitutions: K326W and E333S (according to the EU numbering system).

[0064] In certain embodiments, the polypeptide to be quantitated according to a method provided herein comprises a human IgG3 CH2 domain. In some embodiments, the engineered mutation in the human IgG3 CH2 domain modulates effector function. In some embodiments, the engineered mutation in the human IgG3 CH2 domain comprises an amino acid substitution at E235 (according to the EU numbering system). In some embodiments, amino acid substitution comprises E235Y.

[0065] In certain embodiments, the polypeptide to be quantitated according to a method provided herein comprises a human IgG4 CH2 domain (or portion thereof). In some embodiments, the engineered mutation in the human IgG4 CH2 domain (or portion thereof) modulates effector function. In some embodiments, the engineered mutation in the human IgG4 CH2 domain (or portion thereof) comprises an amino acid substitution at one (or more) the following residues: S228, F234, L235, F296, G327, and P329 (according to the EU numbering system). In some embodiments, amino acid substitution comprises one (or more) of the following amino acid substitutions: S228P, F234A, F234L, L235A, F296Y, G327A, P329G, and P329N.

[0066] In some embodiments, polypeptide to be quantitated according to a method provided herein comprises a CH3 domain (or a portion thereof, e.g., between 10 and 50 amino acids) that comprises an engineered mutation. In some embodiments, the CH3 domain extends from about residue 341 to about residue 447, according to the EU numbering system. *See, e.g.,* International Immunogenetics Information System (IMGT) Web Resources at WorldWideWeb.imgt.org/IMGTScientificChart/Numbering/Hu_IGHGnber.html. These amino acid positions are based on human IgG; however, is not intended that methods provided herein be limited to use with polypeptides comprising the CH3 domain of a human IgG. Corresponding CH3 domain sequences from other human Igs are publicly available, as are the corresponding CH3 domain sequences from other Igs of other mammals (*e.g.,* macaque, cynomolgus monkey, rat, mouse, etc.). In certain embodiments, the engineered mutation in the CH3 domain (or portion thereof) is an amino acid substitution, insertion, or deletion that does not affect (or substantially affect) the desired activity of the polypeptide comprising the antibody heavy chain constant region. In some embodiments, a substitution or insertion comprises the substitution or insertion of an unnatural amino acid or a conjugated amino acid.

[0067] In certain embodiments, the polypeptide to be quantitated according to a method provided herein comprises a human IgG4 CH3 domain (or portion thereof). In some embodiments, the engineered mutation in the human IgG1 CH4 domain (or portion thereof) modulates effector function. In some embodiments, the engineered mutation in the human IgG1 CH3 domain (or portion thereof) comprises (such as consists of) an amino acid substitution at residues R409 (according to the EU numbering system). In some embodiments, the engineered mutation in the human IgG1 CH3 domain (or portion thereof) comprises (such as consists of) the amino acid substitution R409K.

[0068] In certain embodiments, the polypeptide to be quantitated according to a method provided herein comprises a human IgG1 CH3 domain (or portion thereof). In some embodiments, the engineered mutation in the human IgG1 CH3 domain (or portion thereof) modulates effector function and/or improves serum half-life. In some embodiments, the engineered mutation in the human IgG1 CH3 domain (or portion thereof) comprises an amino acid substitution at one or more) of the following residues: N343, E380, E382, P396, M428, H433, N434, and Y436 (according to the EU numbering system). In some embodiments, the engineered mutation in the human IgG1 CH3 domain (or portion thereof) comprises one (or more) of following amino acid substitutions: N343A, E380A, E382V, P396L, M428I, M428L, H433K, N434S, N434F, and Y436H (according to the EU numbering system). In some embodiments, the engineered mutation in the human IgG1CH3 domain (or portion thereof) drives Fc heterodimerization (*e.g.*, for the production of bispecific antibodies, multispecific antibodies, or one-armed antibodies). In some embodiments, the engineered mutation in the human IgG1 CH3 domain (or portion thereof) comprises an amino acid substitution one (or more) of the following residues: Y349, S354, R355, D356, E357, K360, T366, L368, K370, K392, T394, D399, F405, Y407, K409, and K439 (according to the EU numbering system). In some embodiments, the engineered mutation in the human IgG1 CH3 domain (or portion thereof) comprises one (or more) of the following amino acid substitutions: Y349C, S354C, R355D, R355E, D356K, D356R, E357K, E357R, K360D, K360E, T366R, T366K, T366N, T366Q, T366Y, T366W, T366S, T366E, T366G, L368A, L368K, L368Q, L368D, L368E, L368G, L368H, L368I, L368N, L368R, L368S, L368T, L368V, L368W, K370W, K370D, K370E, K392D, K392E, T394W, T394S, D399A, D399G, D399I, D399L, D399M, D399N, D299S, D399T, D399F, D399H, D399K, D399R, D399Y, F405A, F405W, Y407T, Y407V,

Y407A, K409R, K409A, K409H, K409D, K409E, K409G, K439D, and K439E (according to the EU numbering system).

[0069] In some embodiments, the engineered mutation in the human IgG1 CH3 domain (or portion thereof) comprises (such as consists of) Y407V. In some embodiments, the polypeptide comprising an antibody heavy chain constant region with an engineered mutation comprises an amino acid sequence set forth in SEQ ID NO: 6 (DGSFFLVLS). In some embodiments, digestion of a sample comprising (or suspected of comprising) a polypeptide comprising an antibody heavy chain constant region with an engineered Y407V mutation produces a peptide fragment comprising (such as consisting of) the amino acid sequence TTPPVLDSDGSFFLVSK (SEQ ID NO: 7), DGSFFLVSKLTV (SEQ ID NO: 8), or GSFFLVSKLTV (SEQ ID NO: 9). In some embodiments, the sample comprising (or suspected of comprising) a polypeptide comprising an antibody heavy chain constant region with an engineered Y407V mutation is digested with trypsin, and digestion produces a peptide fragment comprising (such as consisting of) the amino acid sequence TTPPVLDSDGSFFLVSK (SEQ ID NO: 7). In some embodiments, the sample comprising (or suspected of comprising) a polypeptide comprising an antibody heavy chain constant region with an engineered Y407V mutation is digested with Asp-N, and digestion produces a peptide fragment comprising (such as consisting of) the amino acid sequence DGSFFLVSKLTV (SEQ ID NO: 8). In some embodiments, the sample comprising (or suspected of comprising) a polypeptide comprising an antibody heavy chain constant region with an engineered Y407V mutation is digested with Glu-C, and digestion produces a peptide fragment comprising (such as consisting of) the amino acid sequence GSFFLVSKLTV (SEQ ID NO: 9).

[0070] In some embodiments, the engineered mutation in the human IgG1 CH3 domain comprises (such as consists of) N434S. In some embodiments, the sample comprising (or suspected of comprising) a polypeptide comprising an antibody heavy chain constant region with an engineered N434S mutation is digested with Glu-C and trypsin, and digestion produces a peptide fragment comprising (such as consisting of) the amino acid sequence ALHSHYTQK (SEQ ID NO: 11).

[0071] In certain embodiments, the engineered mutation is introduced into the antibody heavy chain constant region (or portion thereof) via standard molecular biological techniques known in the art. A variety of methods for genetic engineering have been previously described.

Such mutagenesis methods include, but are not limited to, *e.g.*, error-prone PCR, loop shuffling, oligonucleotide-directed mutagenesis, random nucleotide insertion or other methods prior to recombination. Further details regarding these methods are described in, *e.g.*, Abou-Nadler *et al.* (2010) *Bioengineered Bugs*. 1, 337-340; Firth *et al.* (2005) *Bioinformatics*. 21, 3314-3315; Cirino *et al.* (2003) *Methods Mol Biol*. 231, 3-9; Pirakitikulr (2010) *Protein Sci*. 19, 2336-2346; Steffens *et al.* (2007) *J. Biomol Tech*. 18, 147-149; and others.

Polypeptides Comprising a Portion of an Antibody Heavy Chain Constant Region

[0072] The methods provided herein can be performed using any polypeptide that comprises a portion of an antibody heavy chain constant region, wherein the portion of the antibody heavy chain constant region comprises an engineered mutation. In some embodiments, the polypeptide comprises all or a portion (*e.g.*, 10 to 50 amino acids) of a CH1 domain, CH2 domain, and/or CH3 domain, provided that the domain(s) (or portion(s) thereof) comprise an engineered mutation (*e.g.*, an engineered mutation described elsewhere herein). In some embodiments, the portion of the heavy chain constant domain comprising an engineered mutation is or is derived from a mammal (*e.g.*, a human, a non-human primate, a mouse, a rat, *etc.*). In some embodiments, the portion of the heavy chain constant region that comprises an engineered mutation is or is derived from a human IgG (such as an IgG1, IgG2, IgG3, or IgG4), a human IgA (such as an IgA1 or IgA2), a human IgM, a human IgE, or a human IgD. In some embodiments, the portion of the heavy chain constant region that comprises an engineered mutation is or is derived from a mouse (such as a mouse IgA, IgD, IgE, IgG1, IgG2a, IgG2b, IgG2c, IgG3, or IgM antibody heavy chain constant region).

[0073] In certain embodiments, the polypeptide comprising a portion of antibody heavy chain constant region with an engineered mutation is an antibody. In some embodiments, the antibody is a human, humanized, or chimeric antibody. In some embodiments the antibody comprises a constant region of, *e.g.*, a human IgG1, human IgG2, human IgG3, human IgG4, human IgA1, human IgA2, human IgM, human IgE, or human IgD, that comprises at least one engineered mutation.

[0074] In certain embodiments, the polypeptide comprising a portion of antibody heavy chain constant region with an engineered mutation is a fusion polypeptide. In some embodiments, the fusion polypeptide is an Fc-fusion polypeptide, which comprises the Fc domain (*i.e.*, the CH2 and CH3 domains) of an antibody heavy chain constant region. In some

embodiments, the fusion polypeptide is an immunoadhesin, *i.e.*, a fusion polypeptide in which the functional domain of a binding protein (*e.g.*, a receptor, ligand, or cell-adhesion polypeptide) is fused to a portion of an antibody heavy chain constant region (typically the hinge and Fc domain).

Antibodies

[0075] In some embodiments, the polypeptide comprising a portion of an antibody heavy chain constant region that comprises an engineered mutation is an antibody. In some embodiments, the antibody is a heterotetrameric complex that comprises two light (L) chains and two heavy (H) chains. In some embodiments, the two light chains and the two heavy chains are identical. In some embodiments, the two light chains comprise different amino acid sequences. In some embodiments, the two heavy chains comprise different amino acid sequences. In some embodiments, the antibody is a full length antibody (*e.g.*, comprising two full-length light chains and two full-length heavy chains). In some embodiment, the antibody is an antibody fragment that comprises a portion of a heavy chain constant domain that comprises an engineered mutation, *e.g.*, a Fab, a F(ab')₂, a Fab'-SH, an Fv, an scFv, or a single heavy chain antibody. In certain embodiments, the antibody is mammalian antibody (such as a human antibody, a non-human primate antibody, a mouse antibody, a rat antibody, *etc.*). In some embodiments, the antibody is a monospecific antibody. In some embodiments, the antibody is a multispecific antibody.

Multispecific Antibodies

[0076] Multispecific antibodies possess binding specificities against more than one antigen (*e.g.*, two, three, or more than three binding specificities). In some embodiments, the antibody quantified using a method provided herein is a bispecific antibody. In some embodiments, a bispecific antibody comprises two different binding specificities for the same antigen (*e.g.*, having different binding affinity and/or specific epitope of the same antigen). In some embodiments, a bispecific antibody comprises binding specificities for two different antigens. In some embodiments, the bispecific antibody is a full-length or intact antibody. The methods provided herein are contemplated for use with bispecific or multispecific antibody formats known in the art. Exemplary bispecific and multispecific antibody formats include, but are not limited to, those described below.

[0077] For example, “knobs-into-holes” is a design strategy for engineering antibody heavy chain homodimers for heterodimerization (*e.g.*, for the production of bispecific antibodies, multispecific antibodies, or one-armed antibodies). Generally, such technology involves introducing a protuberance (“knob”) at the interface of a first polypeptide (such as a first CH3 domain in a first antibody heavy chain) and a corresponding cavity (“hole”) in the interface of a second polypeptide (such as a second CH3 domain in a second antibody heavy chain), such that the protuberance can be positioned in the cavity so as to promote heterodimer formation and hinder homodimer formation. Protuberances are constructed by replacing small amino acid side chains from the interface of the first polypeptide (such as a first CH3 domain in a first antibody heavy chain) with larger side chains (*e.g.* arginine, phenylalanine, tyrosine or tryptophan). Compensatory cavities of identical or similar size to the protuberances are created in the interface of the second polypeptide (such as a second CH3 domain in a second antibody heavy chain) by replacing large amino acid side chains with smaller ones (*e.g.* alanine, serine, valine, or threonine). See, *e.g.*, U. S. Patent Nos. 5,731,168; 5,807,706; 5,821,333; 7,642,228; 7,695,936; 8,216,805; and 8,679,785, the contents of each of which are incorporated by reference herein in their entirety. Exemplary sets of knobs-into-holes mutations include, but not limited to, those shown in *Table 1* below:

Table 1. Exemplary Sets of “Knobs-into-Holes” Mutations

Fc domain monomer 1	Y407T	Y407A	F405A	T394S	T366S L368A Y407V	T394 WY40 7T	T394S Y407A	T366 W T394S	S354C T366 W	S354C T366 W
Fc domain monomer 2	T366Y	T366 W	T394 W	F405W	T366 W	T366Y F405A	T366 W F405W	F405W Y407A	Y349C T366S L368A Y407V	Y349C T366S L368A Y407A

[0078] WO 2011/131746 describes a bispecific antibody comprising asymmetrical mutations at one of positions 366, 368, 370, 399, 405, and 407 (according to EU numbering) in each CH3 domain. The mutations drive directional “Fab-arm” or “half-molecule” exchange between two monospecific IgG1, IgG4 or IgG4-like antibodies upon incubation under reducing conditions.

[0079] US 2009/0232811 and Schaefer *et al.* (2011) *PNAS USA*. 108(27): 11187-11192 describe Crossmab technology, *i.e.*, a bispecific antibody format that involves exchanging one or more heavy chain and light chain domains within the antigen-binding fragment (Fab) of one half

of the bi-specific antibody. Correct association of the light chains and their cognate heavy chains is achieved by exchange of heavy-chain and light-chain domains within the antigen binding fragment (Fab) of one half of the bispecific antibody. This “crossover” retains the antigen-binding affinity but makes the two arms so different that light-chain mispairing can no longer occur. Exemplary Crossmab formats include Crossmab^{Fab} (*i.e.*, in which the CL and VL domains are exchanged with the CH1 and VH domains, respectively), Crossmab^{VH-VL} (*i.e.*, in which the VL and VH domains are exchanged), and Crossmab^{CH1-VCL} (*i.e.*, in which the CH1 and CL domains are exchanged). *See also* WO 2009/080251, WO 2009/080252, WO 2009/080253, and WO 2009/080254, the contents of each of which is incorporated herein by reference in their entirety.

[0080] WO 2007/147901 describes a strategy for engineering antibody heavy chains for heterodimerization (*e.g.*, for the production of bispecific antibodies, multispecific antibodies, or one-armed antibodies) that entails introducing asymmetrical mutations in the Fc domains (*i.e.*, K253E, D282K, K322D into a first Fc domain and D239K, E240K, and K292D into a second Fc domain) and in the CH/CL domains (*i.e.*, K96E in the CH1 and E15K in the CL). Such asymmetrical mutations are reported to both disrupt ionic interactions that stabilize homodimerization of half-antibodies and promote heterodimerization of Fc domains.

[0081] WO 2009/089004 describes heteromultimeric proteins (*e.g.*, bispecific, multispecific, or one-armed antibodies) comprising asymmetrical pairs of mutations in the CH3-CH3 interface that make Fc homodimerization electrostatically unfavorable but make Fc heterodimerization electrostatically favorable. *See, e.g.*, Tables 2a and 2b in WO 2009/089004).

[0082] Several antibody-like-proteins with CODV (cross-over dual variable) are described in Steinmetz *et al.* (2016) *MABS*. 8(5): 867-878, WO 2012/135345, WO2016/116626 and U.S. Patent Nos. 9,181,349 9,221,917, the contents of each of which is incorporated herein by reference in their entirety. CODV architecture results in a circular, self-contained structure functioning as a self-supporting truss that maintains the parental antibody affinities for both antigens. A CODV antibody-like protein may be (a) bivalent and/or bispecific; (b) trivalent and/or trispecific; (c) trivalent and/or bispecific; or (d) tetravalent and/or bispecific. In one exemplary format, the polypeptide comprises two polypeptide chains having a structure represented by the formula: V_{L1}-L₁-V_{L2}-L₂-C_L, and two polypeptide chains have a structure represented by the formula: V_{H2}-L₃-V_{H1}-L₄-C_{H1}-Fc, wherein V_{L1} is a first immunoglobulin light

chain variable domain; V_{L2} is a second immunoglobulin light chain variable domain; V_{H1} is a first immunoglobulin heavy chain variable domain; V_{H2} is a second immunoglobulin heavy chain variable domain; C_L is an immunoglobulin light chain constant domain; C_{H1} is the immunoglobulin C_{H1} heavy chain constant domain; Fc comprises an immunoglobulin hinge region and C_{H2} , C_{H3} immunoglobulin heavy chain constant domains; L_1 , L_2 , L_3 , and L_4 are amino acid linkers; and wherein the polypeptides of formula I and the polypeptides of formula II form a cross-over light chain-heavy chain pair. In another exemplary format, the polypeptide comprises two polypeptide chains that form two antigen binding sites, wherein the first polypeptide has a structure represented by the formula: $V_{L1}-L_1-V_{L2}-L_2-CL-Fc$, and the second polypeptide chain has a structure represented by the formula: $V_{H2}-L_3-V_{H1}-L_4-C_{H1}-Fc$, wherein: V_{L1} is a first immunoglobulin light chain variable domain; V_{L2} is a second immunoglobulin light chain variable domain; V_{H1} is a first immunoglobulin heavy chain variable domain; V_{H2} is a second immunoglobulin heavy chain variable domain; CL is an immunoglobulin light chain constant domain; C_{H1} is the immunoglobulin $CH1$ heavy chain constant domain; C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain; C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain; Fc comprises an immunoglobulin hinge region and C_{H2} , C_{H3} immunoglobulin heavy chain constant domains; and L_1 , L_2 , L_3 , and L_4 are amino acid linkers; wherein the first and second polypeptides form a cross-over light chain-heavy chain pair. In a third exemplary format, the polypeptide comprises three polypeptide chains that form two antigen binding sites, wherein the first polypeptide chain has a structure represented by the formula: $V_{L1}-L_1-V_{L2}-L_2-CL$, the second polypeptide chain has a structure represented by the formula: $V_{H2}-L_3-V_{H1}-L_4-C_{H1}-Fc$, the third polypeptide chain comprises an antibody Fc region, wherein: V_{L1} is a first immunoglobulin light chain variable domain; V_{L2} is a second immunoglobulin light chain variable domain; V_{H1} is a first immunoglobulin heavy chain variable domain; V_{H2} is a second immunoglobulin heavy chain variable domain; CL is an immunoglobulin light chain constant domain; C_{H1} is the immunoglobulin $CH1$ heavy chain constant domain; C_{H2} is an immunoglobulin C_{H2} heavy chain constant domain; C_{H3} is an immunoglobulin C_{H3} heavy chain constant domain; Fc comprises an immunoglobulin hinge region and C_{H2} , C_{H3} immunoglobulin heavy chain constant domains; and L_1 , L_2 , L_3 , and L_4 are amino acid linkers; wherein the first and second polypeptides form a cross-over light chain-heavy chain pair. In a fourth exemplary format, the polypeptide comprises a first polypeptide chain comprising a structure represented by the formula: $V_{L1}-L_1-V_{L2}-L_2-C_L$ and a second polypeptide chain comprising a structure

represented by the formula: $V_{H2}-L_3-V_{H1}-L_4-C_{H1}$ wherein: V_{L1} is a first immunoglobulin light chain variable domain; V_{L2} is a second immunoglobulin light chain variable domain; V_{H1} is a first immunoglobulin heavy chain variable domain; V_{H2} is a second immunoglobulin heavy chain variable domain; C_L is an immunoglobulin light chain constant domain; C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain; and L_1 , L_2 , L_3 and L_4 are amino acid linkers; wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

[0083] A bispecific tetravalent immunoglobulin known as the tetravalent bispecific tandem immunoglobulin (TBTI) or dual variable domain immunoglobulin (DVD-Ig) was first described in Wu *et al.* (2007) *Nat Biotechnol.* 25:1290–7. Like a conventional IgG, a TBTI-DVD-Ig comprises two heavy chains and two light chains. However, both heavy and light chains of a TBTI-DVD-Ig comprise an additional variable domain connected via a flexible, naturally occurring linker sequence at the N-termini of the VH and VL of an existing monoclonal antibody. Accordingly, when the heavy and the light chains combine, the resulting TBTI-DVD-Ig comprises four antigen recognition sites. See also U.S. Patent Nos. 9,029,508; 9,109,026; 9,035,027; 9,046,513; 8,388,965; 9,732,162; 9,738,728; European Patent No. 2573121 B1, as well as WO2012/135345, the contents of each of which is incorporated herein by reference in their entirety.

[0084] US 2017/00320967 and WO 2017/180913, the contents of which are expressly incorporated herein by reference in their entireties, describe a binding protein (such as a trivalent and/or trispecific antibody) comprising four polypeptide chains that form three antigen binding sites. In some embodiments, the binding protein is trivalent. In some embodiments, the binding protein is trispecific. In one exemplary format, the first polypeptide chain comprises a structure represented by the formula: $V_{L2}-L_1-V_{L1}-L_2-CL$; the second polypeptide chain comprises a structure represented by the formula: $V_{H1}-L_3-V_{H2}-L_4-C_{H1}$ -hinge- $C_{H2}-C_{H3}$; the third polypeptide chain comprises a structure represented by the formula: $V_{H3}-C_{H1}$ -hinge- $C_{H2}-C_{H3}$; the fourth polypeptide chain comprises a structure represented by the formula: $V_{L3}-CL$, wherein V_{L1} is a first immunoglobulin light chain variable domain; V_{L2} is a second immunoglobulin light chain variable domain; V_{L3} is a third immunoglobulin light chain variable domain; V_{H1} is a first immunoglobulin heavy chain variable domain; V_{H2} is a second immunoglobulin heavy chain variable domain; V_{H3} is a third immunoglobulin heavy chain variable domain; C_L is an immunoglobulin light chain constant domain; C_{H1} is an immunoglobulin C_{H1} heavy chain

constant domain; and L₁, L₂, L₃ and L₄ are amino acid linkers; wherein the first and second polypeptides form a cross-over light chain-heavy chain pair; and wherein the second polypeptide chain or the third polypeptide chain comprises the amino acid sequence

TTPPVLDSDGSFFLVSK (SEQ ID NO: 7), DGSFFLVSKLTV (SEQ ID NO: 8), or GSFFLVSKLTV (SEQ ID NO: 9).

[0085] In some embodiments, the linkers L₁, L₂, L₃, and L₄ range from no amino acids (length = 0) to about 100 amino acids long, or less than 100, 50, 40, 30, 20, or 15 amino acids or less. The linkers can also be 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acids long. L₁, L₂, L₃, and L₄ in one binding protein may all have the same amino acid sequence or may all have different amino acid sequences.

[0086] Examples of suitable linkers include a single glycine (Gly) residue; a diglycine peptide (Gly-Gly); a tripeptide (Gly-Gly-Gly); a peptide with four glycine residues (Gly-Gly-Gly-Gly; SEQ ID NO: 21); a peptide with five glycine residues (Gly-Gly-Gly-Gly-Gly; SEQ ID NO: 22); a peptide with six glycine residues (Gly-Gly-Gly-Gly-Gly-Gly; SEQ ID NO: 23); a peptide with seven glycine residues (Gly-Gly-Gly-Gly-Gly-Gly-Gly; SEQ ID NO: 24); a peptide with eight glycine residues (Gly-Gly-Gly-Gly-Gly-Gly-Gly-Gly; SEQ ID NO: 25). Other combinations of amino acid residues may be used such as the peptide Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 26), the peptide Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 27) and the peptide Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 28). Other suitable linkers include a single Ser, and Val residue; the dipeptide Arg-Thr, Gln-Pro, Ser-Ser, Thr-Lys, and Ser-Leu; Thr-Lys-Gly-Pro-Ser (SEQ ID NO: 29), Thr-Val-Ala-Ala-Pro (SEQ ID NO: 30), Gln-Pro-Lys-Ala-Ala (SEQ ID NO: 31), Gln-Arg-Ile-Glu-Gly (SEQ ID NO: 32), Ala-Ser-Thr-Lys-Gly-Pro-Ser (SEQ ID NO: 33), Arg-Thr-Val-Ala-Ala-Pro-Ser (SEQ ID NO: 34), Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 35), and His-Ile-Asp-Ser-Pro-Asn-Lys (SEQ ID NO: 36). The examples listed above are not intended to limit the scope of the disclosure in any way, and linkers comprising randomly selected amino acids selected from the group consisting of valine, leucine, isoleucine, serine, threonine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, glycine, and proline have been shown to be suitable in the binding proteins.

[0087] The identity and sequence of amino acid residues in the linker may vary depending on the type of secondary structural element necessary to achieve in the linker. For example,

glycine, serine, and alanine are best for linkers having maximum flexibility. Some combination of glycine, proline, threonine, and serine are useful if a more rigid and extended linker is necessary. Any amino acid residue may be considered as a linker in combination with other amino acid residues to construct larger peptide linkers as necessary depending on the desired properties.

[0088] In some embodiments, the length of L_1 is at least twice the length of L_3 . In some embodiments, the length of L_2 is at least twice the length of L_4 . In some embodiments, the length of L_1 is at least twice the length of L_3 , and the length of L_2 is at least twice the length of L_4 . In some embodiments, L_1 is 3 to 12 amino acid residues in length, L_2 is 3 to 14 amino acid residues in length, L_3 is 1 to 8 amino acid residues in length, and L_4 is 1 to 3 amino acid residues in length. In some embodiments, L_1 is 5 to 10 amino acid residues in length, L_2 is 5 to 8 amino acid residues in length, L_3 is 1 to 5 amino acid residues in length, and L_4 is 1 to 2 amino acid residues in length. In some embodiments, L_1 is 7 amino acid residues in length, L_2 is 5 amino acid residues in length, L_3 is 1 amino acid residue in length, and L_4 is 2 amino acid residues in length.

[0089] In some embodiments, L_1 , L_2 , L_3 , and/or L_4 comprise the sequence Asp-Lys-Thr-His-Thr (SEQ ID NO: 35). In some embodiments, L_1 comprises the sequence Asp-Lys-Thr-His-Thr (SEQ ID NO: 35). In some embodiments, L_3 comprises the sequence Asp-Lys-Thr-His-Thr (SEQ ID NO: 35).

[0090] In some embodiments, L_1 , L_2 , L_3 , and/or L_4 comprise the sequence Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 33). In some embodiments, L_1 comprises the sequence Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 33). In some embodiments, L_1 comprises the sequence Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 33), L_2 comprises the sequence Thr-Lys-Gly-Pro-Ser-Arg (SEQ ID NO: 36), L_3 comprises the sequence Ser, and L_4 comprises the sequence Arg-Thr. In some embodiments, L_3 comprises the sequence Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 33). In some embodiments, L_1 comprises the sequence Ser, L_2 comprises the sequence Arg-Thr, L_3 comprises the sequence Gly-Gln-Pro-Lys-Ala-Ala-Pro (SEQ ID NO: 33) and L_4 comprises the sequence Thr-Lys-Gly-Pro-Ser-Arg (SEQ ID NO: 36).

[0091] In some embodiments, the first polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 12; the second polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 13; the third polypeptide comprises the amino acid sequence set forth in SEQ ID

NO: 14, and the fourth polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 15. (SEQ ID NOs: 12, 13, 14, and 15 correspond to SEQ ID NOs: 3, 4, 1, and 2 disclosed in WO 2017/074878, respectively.) The amino acid sequences of additional exemplary trispecific antibodies are described in WO 2017/074878, the contents of which are incorporated herein by reference in their entirety.

[0092] The strand-exchange engineered domain (SEED) platform, designed to generate asymmetric and bispecific antibody-like molecules, is based on exchanging structurally related sequences of immunoglobulin within the conserved CH3 domains. Alternating sequences from human IgA and IgG in the SEED CH3 domains generate two asymmetric but complementary domains, designated AG and GA. The SEED design allows efficient generation of AG/GA heterodimers and disfavors the formation of AG/AG and GA/GA homodimers. *See, e.g.,* Muda *et al.* (2011) *Prot Engineering, Design & Selection*. 24(5): 447-454 and U.S. Patent No. 8,871,912, the contents of which are incorporated herein by reference in their entirety.

[0093] Other bispecific and multispecific antibody formats are described Klein *et al.*, (2012) *mAbs* 4:6, 653-663; Spiess *et al.* (2015) "Alternative molecular formats and therapeutic applications for bispecific antibodies." *Mol. Immunol.* 67(2 Pt A): 95-106; Egan *et al.* (2017) *mAbs*. 9(1):68-84; Liu *et al.* (2017) *Front Immunol.* 8: 38; and Weidle *et al.* (2013) *Cancer Genomics Proteomics*. 10(1): 1-18.

Target Antigens

[0094] In certain embodiments, a polypeptide to be quantified according to a method provided herein (*i.e.*, a polypeptide comprising a portion of an antibody heavy chain constant region that comprises an engineered mutation) specifically binds to a target antigen. Exemplary target antigens include, without limitation, A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H4 (also known as VTCN1), B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2 (also known as MCP-1), CCL3 (also known as MIP-1a), CCL4 (also known as MIP-1b), CCL5 (also known as RANTES), CCL7 (also known as MCP-3), CCL8 (also known as mcp-2), CCL11 (also known as eotaxin), CCL15 (also known as MIP-1d), CCL17 (also known as TARC), CCL19 (also known as MIP-3b), CCL20 (also known as MIP-3a), CCL21 (also known as MIP-2), CCL24 (also known as MPIF-2/eotaxin-2), CCL25 (also known as TECK), CCL26 (also known as eotaxin-3), CCR3, CCR4, CD3, CD19, CD20, CD23 (also known as FCER2, a receptor for IgE), CD24, CD27, CD28, CD38, CD39, CD40, CD70,

CD80 (also known as B7-1), CD86 (also known as B7-2), CD122, CD137 (also known as 41BB), CD137L, CD152 (also known as CTLA4), CD154 (also known as CD40L), CD160, CD272, CD273 (also known as PDL2), CD274 (also known as PDL1), CD275 (also known as B7H2), CD276 (also known as B7H3), CD278 (also known as ICOS), CD279 (also known as PD-1), CDH1 (also known as E-cadherin), chitinase, CLEC9, CLEC91, CRTH2, CSF-1 (also known as M-CSF), CSF-2 (also known as GM-CSF), CSF-3 (also known as GCSF), CX3CL1 (also known as SCYD1), CXCL12 (also known as SDF1), CXCL13, CXCR3, DNGR-1, ectonucleoside triphosphate diphosphohydrolase 1, EGFR, ENTPD1, FCER1A, FCER1, FLAP, FOLH1, Gi24, GATR, GITRL, GM-CSF, Her2, HHLA2, HMGB1, HVEM, ICOSLG, IDO, IFN α , IgE, IGF1R, IL2Rbeta, IL1, IL1A, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL10, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb (also known as a receptor for IL25), IL18, IL22, IL23, IL25, IL27, IL33, IL35, ITGB4 (also known as b4 integrin), ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, NCR3LG1, NKG2D, NTPDase-1, OX40, OX40L, PD-1H, platelet receptor, PROM1, S152, SISP1, SLC, SPG64, ST2 (also known as a receptor for IL33), STEAP2, Syk kinase, TACI, TDO, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNF α , TNFRSF7, Tp55, TREM1, TSLP (also known as a co-receptor for IL7Ra), TSLPR, TWEAK, VEGF, VISTA, Vstm3, WUCAM, and XCR1 (also known as GPR5/CCXCR1). In some embodiments, one or more of the above antigen targets are human antigen targets. In embodiments wherein the polypeptide comprising an antibody heavy chain constant region that comprises an engineered mutation is a bispecific or multispecific target binding protein, the target antigens may be any two (or more) of the exemplary antigens listed above.

Conjugates

[0095] In some embodiments, a polypeptide to be quantified according to a method provided herein (*i.e.*, a polypeptide comprising an antibody heavy chain constant region that comprises an engineered mutation) is conjugated to a drug, *e.g.*, a cytotoxic agent, a chemotherapeutic agent, a growth inhibitory agent, a toxin (*e.g.*, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof). Exemplary drugs include, without limitation, daunomycin, doxorubicin, methotrexate, vindesine, BCNU, streptozocin, vincristine, and 5-fluorouracil. Exemplary toxins include, without limitation, diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin, geldanamycin, maytansine (or other maytansinoids), auristatins, dolastatin, calicheamicin, abrin A chain,

modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolacca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, tricothecenes, and CC1065. Cytotoxic agents and linkers that conjugate the agents to an antibody are known in the art; see, e.g., Parslow, A.C. *et al.* (2016) *Biomedicines* 4:14 and Kalim, M. *et al.* (2017) *Drug Des. Devel. Ther.* 11:2265-2276.

[0096] In some embodiments, a polypeptide to be quantified according to a method provided herein (*i.e.*, a polypeptide comprising an antibody heavy chain constant region that comprises an engineered mutation) is conjugated to detectable moiety that is capable of producing, either directly or indirectly, a detectable signal. In certain embodiments, the detectable label is a radionuclide. A variety of radionuclides are available for the production of radioconjugated polypeptides for use in clinical and research purposes. Examples include ^{13}C , ^{15}N , ^{17}O , ^{19}F , ^{32}P , ^{90}Y , $^{99\text{m}}\text{Tc}$, ^{111}In , ^{123}I , ^{125}I , ^{131}I , ^{131}In , ^{153}Sm , ^{186}Re , ^{188}Re , ^{211}At , ^{212}Bi , ^{212}Pb , and radioactive isotopes of Lu, Mn, Fe, and Gd. In certain embodiments, the detectable label is a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; or an enzyme, such as alkaline phosphatase, β -galactosidase, or horseradish peroxidase.

[0097] The foregoing written description is considered to be sufficient to enable one skilled in the art to practice the invention. The following Examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Indeed, various modifications in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

EXAMPLES

Example 1: Identifying a surrogate peptide for use in a generic mass spectrometry-based assay for detecting a polypeptide comprising an antibody heavy chain constant region in a sample

[0098] The following selection criteria were applied to identify a surrogate peptide for the detection of a therapeutic antibody in a biological sample via mass spectrometry:

- A length between 6 and 26 amino acids;
- No adjacent endopeptidase cleavage sites;
- No methionine (M) or cysteine (C) in the peptide sequence;

- No asparagine followed by glycine or serine (*i.e.*, NG or NS) in peptide sequence;
- Is derived from the constant region of an antibody heavy chain; and
- Contains at least one engineered substitution mutation (*i.e.*, excluding naturally occurring polymorphisms).

[0099] First, the Fc sequences of three exemplary therapeutic antibodies were aligned. *See FIG. 1.* SEQ ID NO: 1 is a portion of an anti-Target A antibody heavy chain. SEQ ID NO: 1 does not comprise an engineered mutation. SEQ ID NO: 2 is a portion of a first chain (*i.e.*, “chain 1”) of a trispecific construct (*i.e.*, “TRI-1”). TRI-1-chain 1 comprises an antibody heavy chain that comprises S354C and T366W mutations (*i.e.*, “knob” mutations) and M428L/N434S mutations (which extend the *in vivo* half-life of TRI-1). SEQ ID NO: 3 is a portion of a second chain (*i.e.*, “chain 2”) chain of TRI-1. TRI-1-chain 2 comprises an antibody heavy chain that comprises Y349C/T366S/368A/407 V “hole” mutations and M428L/N434S mutations. SEQ ID NO: 4 is a portion of a first chain (*i.e.*, “chain 1”) of a second trispecific construct (*i.e.*, “TRI-2”). TRI-2-chain 1 comprises an antibody heavy chain that comprises Y349C/T366S/368A/407 V mutations (*i.e.*, “hole” mutations) and M428L/N434S mutations. SEQ ID NO: 5 is a portion of a second chain (*i.e.*, “chain 2”) of TRI-2. TRI-2-chain 2 comprises a heavy chain that comprises S354C/T366W “knob” mutations and M428L/N434S mutations. All amino acid positions discussed above are numbered according to the EU numbering scheme.

[0100] Candidate peptides containing at least one engineered substitution mutation that were predicted to result from tryptic digestion of the sequences shown in **FIG. 1** are underlined. The peptide TTPPVLDSDGSFFLVSK (SEQ ID NO: 7), met all the criteria listed above.

[0101] Next, BLAST searches were performed using TTPPVLDSDGSFFLVSK (SEQ ID NO: 7), *i.e.*, the “engineered TTPP peptide,” as a query sequence against mouse, cynomolgus monkey, and human protein databases to determine whether such sequence is found in any native proteins in these species. The only sequences exhibiting 100% amino acid identity to the engineered TTPP peptide were known knob-in-hole antibodies. Other sequences that exhibited 94% amino acid identity to the engineered TTPP peptide corresponded to human Fc domains containing Y407 substitution mutations other than Y407V and endogenous human Fc domains.

[0102] The experiments described below were performed to assess the feasibility with which trypsin digestion of the trispecific construct TRI-1 gave rise to the engineered TTPP peptide.

Briefly, 10 µg of TRI-1 (which comprises SEQ ID NOs: 2 and 3 shown in **FIG. 1**) was digested using the SMART™ Digest Kit (ThermoFisher) according to manufacturer's instructions. The digestion reaction was incubated at 70°C while being shaken at 1400 rpm for 75 minutes. The digested sample was then centrifuged at 1000 x g for 2 min, and the supernatant was collected for purification and concentration.

[0103] The required number of wells in a SOLAµ HRP solid phase extraction (SPE) plate (ThermoFisher) were equilibrated with 200 µL of acetonitrile and then conditioned with 200 µL of 0.1% trifluoroacetic acid (TFA) in water. Then an additional 400 µL of 0.1% TFA in water was added to each well. The sample supernatants were added to the wells and allowed to pass through. The wells were then washed with 500 µL of 0.1% TFA in water and then washed 500 µL of 0.1% formic acid in water. The digested samples were eluted with 2 x 25 µL of 80% acetonitrile in water with 0.1% formic acid. The eluate was diluted with 50 µL of 0.1% formic acid in water and vortexed briefly at 400 rpm.

[0104] 50 µL of each digested sample was analyzed via liquid chromatography-tandem mass spectrometry using a Waters H-Class Acquity UPLC coupled to a Thermo QExactive mass spectrometer run in typical peptide mapping conditions.

[0105] As shown in **FIGs. 2A-2C**, trypsin digestion of TRI-1 reproducibly gave rise to the engineered TTPP peptide, and the peptide was easily detected and fragmented. The extracted ion chromatogram for m/z of 905.40-907.60, a subset of the natural isotopic range of engineered TTPP is shown in **FIG. 2A**. Engineered TTPP eluted at about 19 minutes. Within the total ion chromatograph (shown in **FIG. 2B**), engineered TTPP was a prominent peak. Furthermore, engineered TTPP showed good fragmentation for MS/MS analysis (**FIG. 2C**).

Example 2: Detection of the TTPP peptide in Serum

[0106] Next, a series of experiments was performed to determine whether the engineered TTPP peptide could be detected in human, monkey, and mouse sera via LC-MS/MS without significant background interference. Mouse and cynomolgus monkey sera were tested, as these animals are commonly used in pre-clinical therapeutic antibody studies.

[0107] Briefly, 100 µL of vortexed Protein G magnetic beads (Pierce) and 100 µL of PBST were added into wells in a 96-well microplate (Qiagen). The plate was gently shaken to ensure a homogenous mixture. The 96-well plate was placed on an Alpaqua 96S Super Magnet 96 well magnet for one minute, followed by a Qiagen Type A 96 well magnet for one minute, and then

the solution was removed. This wash cycle was repeated three more times with 200 μ L of PBST. After washing was complete, 140 μ L of PBST were added into each well containing the beads. Then, 30 μ L of (1) mouse serum, (2) monkey serum, (3) human serum or (4) 2 μ g/mL TRI-1 was added to the wells. 30 μ L of the calibrators, QC, and samples were added into separate wells containing the beads, PBST, and sera. The 96-well plate was then covered and shaken for 1 hour at 600 RPM and washed four times. The calibrators, QC, and samples were eluted by adding 90 μ L of 0.1% TFA into each well and gently vortexing the plate to ensure a homogeneous mixture. The plate was placed on an Alpaqua 96S Super Magnet 96 well magnet for one minute, followed by a Qiagen Type A 96-well magnet for one minute. Then, the eluate was transferred into a 2.0 mL 96-well deep well Protein LoBind plate (Eppendorf). The elution procedure was then repeated. The pH of the eluate was neutralized with 20 μ L of 1 M tris-HCl pH 8, bringing the total volume to 200 μ L. Briefly, 200 μ L of SMART digest buffer was added to each of the eluates. The samples were incubated at 70 °C with shaking at 400 rpm for 75 minutes and then were centrifuged at 1000 x g for 2 min to pellet the SMART digest resin.

[0108] Wells in a SOLA μ HRP SPE plate were equilibrated with 200 μ L of acetonitrile and then conditioned with 200 μ L of 0.1% TFA in water. An additional 400 μ L of 0.1% TFA in water was added to each well. Each sample supernatant was added to a separate well and allowed to pass through. The wells were washed with 500 μ L of 0.1% TFA in water and then 500 μ L of 0.1% formic acid in water. The digested samples were eluted with 2 x 25 μ L of 80% acetonitrile in water with 0.1% formic acid. The eluate was diluted with 50 μ L of 0.1% formic acid in water and vortexed briefly at 400 rpm.

[0109] SMART digests of sample were analyzed using a Waters H-Class Acquity UPLC and Thermo QExactive mass spectrometer under standard peptide mapping conditions.

[0110] Extracted ion chromatograms for the engineered TTPP peptide (m/z 905.47²⁺) in blank serum are shown in **FIGs. 3A-3C**, and the extracted ion chromatogram for the engineered TTPP peptide in the TRI-1 digest (2 μ g/mL in PBST) is shown in **FIG. 3D**. The peak at 20.65 min in the TRI-1 digest is not present in any of the serum backgrounds tested.

[0111] To confirm that engineered TTPP peptide could be detected in serum backgrounds, mouse, monkey, and human serum samples were spiked with 20 μ g/mL TRI-1 and subject to antibody pulldown, digestion, and mass spectrometry analysis as described above.

[0112] Extracted ion chromatograms for the engineered TTPP peptide (m/z 905.47²⁺) are shown in **FIGs. 4A-4C** and TRI-1 digest in PBST is shown in **FIG. 4D**. Upon spiking TRI-1 into each of the serum backgrounds, engineered TTPP peptide can clearly be seen in all backgrounds.

[0113] Serial dilutions of TRI-1 into the appropriate serum background to final concentrations of 0.2, 2, and 20 $\mu\text{g/mL}$ were prepared to determine whether signal increased proportionally to the amounts of analyte in the sample. Aliquots of serum with no antibody spike in were used as background controls. Pull down, digestion, SPE cleanup, and LC-MS/MS were performed as described above.

[0114] Extracted ion chromatograms of engineered TTPP, unlabeled FNWY, and FNWY (Heavy) derived from analysis of the three tested concentrations of TRI-1 (20, 2, and 0.2 $\mu\text{g/mL}$) in PBST are shown in **FIGs. 5A-5C, 6A-6C, and 7A-7C**, respectively. Extracted ion chromatograms of engineered TTPP, unlabeled FNWY, and FNWY (Heavy) derived from analysis of the four tested concentrations of TRI-1 (20, 2, 0.2, and 0 $\mu\text{g/mL}$) in mouse serum are shown in **FIGs. 8A-8C, 9A-9C, and 10A-10C**, respectively. Extracted ion chromatograms of engineered TTPP, unlabeled FNWY, and FNWY (Heavy) derived from analysis of the four tested concentrations of TRI-1 (20, 2, 0.2, and 0 $\mu\text{g/mL}$) in monkey serum are shown in **FIGs. 11A-11C, 12A-12C, and 13A-13C**, respectively. Extracted ion chromatograms of engineered TTPP derived from analysis of the four tested concentrations of TRI-1 (20, 2, 0.2, and 0 $\mu\text{g/mL}$) in human serum are shown in **FIGs. 14A-14C**.

[0115] The peak areas for the engineered TTPP peptide and the heavy isotope peptide FNWYVDGVEVHNAK (SEQ ID NO: 10) were determined. *See Table 2* below. FNWY(Heavy) is an internal standard derived from the digestion of a stable isotope-labeled universal monoclonal antibody (SILUTM MAB).

Table 2. Summary of Results of Quantification Assay

Background	TRI-1 Concentration ($\mu\text{g/mL}$)	Engineered TTPP Peak Area	FNWY (heavy) Peak Area	FNWY (light-unlabeled) Peak Area	Area Ratio (Engineered TTPP: FNWY(heavy))	Area Ratio (FNWY: FNWY(heavy))
PBST	20	44064886	1369078	70091279	32.2	51.2
	2	2633166	343482	1078300	7.7	3.1
	0.2	368649	473743	209110	0.8	0.4
Mouse Serum	20	11833127	967309	22039621	12.2	22.8
	2	2168471	1199642	2500109	1.8	2.1

Background	TRI-1 Concentration ($\mu\text{g/mL}$)	Engineered TTPP Peak Area	FNWY (heavy) Peak Area	FNWY (light- unlabeled) Peak Area	Area Ratio (Engineered TTPP: FNWY(heavy))	Area Ratio (FNWY: FNWY(heavy))
	0.2	ND	2310675	410330	ND	0.2
Monkey Serum	20	3751017	1344983	13378187	2.8	9.9
	2	1013964	1271728	1298150	0.8	1.0
	0.2	ND	1216254	97731	ND	0.1
Human Serum	20	1848332		NA		NA
	2	194065		NA		NA
	0.2	ND		NA		NA

[0116] The area ratios of engineered TTPP to FNWY(Heavy) for PBST, mouse serum, and monkey serum backgrounds are also shown in *Table 2* and plotted versus input TRI-1 concentration in **FIGs. 15A-D**. The area ratio of engineered FNWY to FNWY(Heavy) for PBST is shown in *Table 2* and plotted versus input antibody concentration in **FIGs. 15A, 15C, and 15D**.

[0117] The data above demonstrate that there is little to no background interference for the TTPP peptide in mouse serum, monkey serum, or human serum, and that signal generated by the TTPP peptide correlates with the amount of peptide in a sample.

Table 3. Amino Acid Sequences in Examples 1 and 2

SEQ ID NO.	SEQUENCE
1	THTCPPCPAP ELLGGPSVFL FPPKPRDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLF PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV FSCSVLHEAL HNHYTQKSLS LSPGK
2	THTCPPCPAP ELLGGPSVFL FPPKPRDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLF PCRDELTKNQ VSLWCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV FSCSVLHEAL HSHYTQKSLS LSPG
3	THTCPPCPAP ELLGGPSVFL FPPKPRDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVCTLF PSRDELTKNQ VSLSCAVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLVSKLTV DKSRWQQGNV FSCSVLHEAL HSHYTQKSLS LSPG
4	THTCPPCPAP ELLGGPSVFL FPPKPRDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVCTLF PSRDELTKNQ VSLSCAVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLVSKLTV DKSRWQQGNV

SEQ ID NO.	SEQUENCE
	FSCSVMEAL HNHYTQKSL LSPGK
5	THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTRPR EEQYNSTYPV VSVLTVLHQD WLNKEYKCK VSNKALPAPI EKTISKARGQ PREPQVYTLF PCRDELTKNQ VSLWCLVKG YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSEWQQGNV FSCSVMEAL HNHYTQKSL LSPGK
6	DGSFFLVS
7	TTPPVLDSDG SFFLVSK
8	DGSFFLVSKL TV
9	GSFFLVSKLT VD
10	FNWYVDGVEV HNAK
11	ALHSHYTQK

Example 3: Use of the TTPP Surrogate Peptide in a Generic Mass Spectrometry-Based Assay for Detecting and Quantifying an Exemplary Trispecific Antibody.

Overview

[0118] Therapeutic antibodies are attractive tools for targeting diseases and their market is growing at fast pace. Ligand-binding assays have been standard methods for measuring therapeutic antibodies. However, in order to provide support for their development, new bioanalytical strategies are necessary. LC-MS/MS represents a complementary method, providing specificity and higher reproducibility requested for Good Laboratory Practice (GLP) studies. Moreover, LC-MS/MS overcomes some limitations associated with ligand-binding assays (LBAs), such as matrix interference (e.g., components in sample that may impede accurate quantification of the therapeutic antibody) and the development of reagents, which can be costly and time-consuming.

[0119] IgGs represent the majority of therapeutic proteins currently in the clinics. In order to reduce immunogenicity, therapeutic antibodies are engineered to comprise human antibody constant region, such as human IgG constant regions. Developing a bioanalytical LC-MS assay to quantitate such therapeutic antibodies has been challenging, as it is difficult to select suitable surrogate peptides that can be used to discriminate between endogenous human IgGs in a sample

(e.g., a plasma, serum or blood sample) and the therapeutic IgG antibody without the help of an immune-affinity step. To overcome this issue, the constant region of an exemplary therapeutic antibody was engineered to comprise a substitution mutation, e.g., a substitution mutation that is not naturally found in human antibody constant regions, or the antibody constant regions of non-human primates or pre-clinical animals (e.g., mice). This stratagem allows an accurate quantification of the therapeutic antibody in both non-human and human samples without matrix interference.

[0120] Described below is an affinity extraction-free LC-MS/MS assay for a fast and accurate quantitation of a trivalent trispecific antibody against a soluble target in plasma. By avoiding an-immuno-affinity step, this method will allow accurate quantification of total drug (sum of target-bound drug plus free drug). Moreover, because the substitution mutation is in the antibody constant region, this method can be used to quantify any therapeutic protein that comprises an antibody constant region.

Analytical Procedure

[0121] The surrogate peptides that were selected for quantification of an exemplary trispecific antibody via LC-MS/MS are shown in **FIGs. 16** and **17** and in **Table 4** below. These surrogate peptides were selected based on their linear response. Peptides whose sequences are not found in human proteins or in the proteins of non-human primates (i.e., SEQ ID NO: 7, 16, and 38) were used. For absolute quantification, the engineered peptide TTPPVLDSDGSFFLVSK (SEQ ID NO: 7) was used (*See FIGs. 16* and *17* and **Table 4** below). In order to assure integrity of the analyte, the ratios between the areas under the peaks of TTPPVLDSDGSFFLVSK (SEQ ID NO: 7) and the other peptides listed in **Table 4** were monitored in the samples that were quantified via LC-MS/MS. The ratios stayed constant at all time points (results not shown).

Table 4. List of Surrogate Peptides and the MS Parameters for their detection

Peptide	Mass Transitions	Collision Energy (V)
TTPPVLDSDGSFFLVSK (SEQ ID NO: 7)	Precursor Ion m/z 905.8 → Product Ion m/z 804.5	37
DTLMISR	Precursor Ion m/z 418.2 →	14

(SEQ ID NO 18)	Product Ion m/z 506.3	
LVIYSGSTR (SEQ ID NO: 16)	Precursor Ion m/z 751.9 → Product Ion m/z 1036.6	21
DSTYSLSSTLTLSK (SEQ ID NO: 17)	Precursor Ion m/z 912.2 → Product Ion m/z 811.0	30
ESPWTFGQGTK (SEQ ID NO: 38)	Precursor Ion m/z 619.3 → Product Ion m/z 738.4	34

[0122] The stable-isotope-labeled version of TTPPVLDSDGSFFLVSK (SEQ ID NO: 7) was used as internal standard (**FIG. 19B**).

[0123] A fast and robust workflow was developed for supporting pre-clinical studies (*see FIG. 18*). The method is based on the pellet digestion protocol described in Ouyang *et al.* (2012) *Bioanalysis*. 4(1), 17–28. Each step in the digestion protocol was optimized to maximize the recovery of the trispecific antibody from the sample and detection of the surrogate peptides. (The workflow for a sample from a human subject included a Protein A immunopurification step prior to the denaturation step.)

[0124] The method used only 10 μ L of a plasma sample. As a small sample volume was sufficient, the surrogate peptide quantification method is suitable for measuring preclinical samples from, e.g., rodents. Standard digestion time was also optimized. The best signal intensity was observed when the sample was digested for two hours at 37°C. To further increase the sensitivity of the quantification method, samples were subjected to solid phase extraction (SPE). The best recovery was obtained using OASIS MCX cartridges.

Validation for rat plasma

[0125] Method validation was performing in rat plasma for supporting a GLP toxicological study. A quadratic regression model was chosen with mean regression coefficient at 0.979 over three independent calibration curve with three replicates for run and 8 nominal concentrations (**FIG. 19A**). Assay variability was assessed by measuring accuracy and precision of quality control (QC) samples at LLOQ (lowest limit of quantification), LOW, MID, and HIGH of three independent preparations. Intra/inter-run accuracy and precision are summarized in **Table 5**. Matrix effect was carried out by using six different plasma batches (*see Table 6* below). Stability

of the antibody in plasma was evaluated in spiked human plasma stored for 1-3 and 6 months at -80°C and at 37°C for 24 h. No degradation was observed during these intervals.

Table 5. Inter- and Intra-Run Accuracy and Precision of three independent samples at LLOQ, LOW, MID, and HIGH

Nominal Concentration (µg/ml)	Mean Calculated Concentration (µg/ml)	Accuracy % Difference Estimate	Intra-Run Percent Precision	Inter-Run Percent Precision
LLOQ 2.5 (n=18)	2.60	4.00	16.2	14.8
QC LOW 7.5 (n=18)	8.10	7.99	5.57	5.01
QC MID 750 (n=18)	827	10.2	4.17	9.31
QC HIGH 7,500 (n=18)	8220	9.53	2.61	8.63

Table 6. Matrix Effect on Six Independent Batches of Rat Plasma

Rat 1 (Male)	Rat 2 (Male)	Rat 3 (Male)	Rat 4 (Female)	Rat 5 (Female)	Rat 6 (Female)
Peak Areas of TTPP Peptide (SEQ ID NO: 7) in Blank Plasma Samples					
22	34	48	84	67	50
31	14	25	61	661	11
11	28	17	148	14	56
Area LLOQ (2.5 µg/mL)					
121217	155613	130475	175238	160757	157595
132624	142140	148339	163371	171581	156564
125229	128498	142467	173085	165758	117524
0.637%	4.58%	5.54%	19.9%	1.74%	2.28%
1.30%	14.2%	1.68%	11.2%	10.4%	1.95%
1.42%	3.44%	0.822%	4.67%	2.90%	9.21%

[0126] Additional experiments were performed to determine whether 5 µg/ml of trispecific antibody could be detected using the surrogate TTPP peptide (SEQ ID NO: 7) when spiked into monkey plasma and human plasma. As shown in **FIGs. 22A-22F**, the TTPP peptide was detected in the spiked rat plasma (**FIG. 22B**), spiked monkey plasma (**FIG. 22D**), and spiked human plasma (**FIG. 22F**), but not in blank rat plasma (**FIG. 22A**), blank monkey plasma (**FIG. 22C**) or blank human plasma (**FIG. 22E**).

[0127] As discussed elsewhere herein, ligand-binding assays (LBAs) such as ELISAs have traditionally been used to detect and quantify therapeutic proteins (e.g., monoclonal antibodies) in biological samples. The quantification of a monoclonal antibody via LBA typically involves using the target antigen as a capture agent or a detection agent. However, LBAs may generate inaccurate results if used to detect trispecific antibody and a soluble target of the trispecific antibody. For a trispecific antibody, quantification via LBA would entail developing three different assays (i.e., one assay per target antigen), which would produce three different concentration datasets, which would not be manageable for preclinical species or human PK exposure assessment. Moreover, it would be difficult to distinguish the amount of free antibody vs. target-bound antibody vs. total antibody in a sample using an LBA. In this Example, a generic LC-MS assay, which can be used in both preclinical and clinical phase, was shown to be capable of measuring a trispecific antibody against a soluble target with high accuracy. The assay was shown to be specific, as demonstrated by the absence of interfering signals in blank plasma samples (*see FIGs. 20A-20F*). This assay was also shown to be reproducible, as shown in **Table 5** with accuracy % difference estimate and inter-run and intra-run % precision within international regulatory acceptance criteria defined by FDA and EMA guidance on bioanalytical method validation (i.e., accuracy % not more than ±20% and precision % not more than ±20%).

Materials and Methods for Preclinical species

[0128] Trispecific antibody was provided as a stock solution with a nominal concentration of 25 mg/mL in 10 mM Histidine, 8% Sucrose, 0.04% polysorbate 80, pH 6.0. Calibration standard and QCs were obtained by diluting the stock solution in rat plasma.

[0129] Pellet digestion of rat plasma containing trispecific antibody was optimized from the procedure previously described in Ouyang *et al.* (2012) *Bioanalysis*. 4(1), 17–28. Briefly, 10 µl of each rat plasma sample containing the trispecific antibody was placed into a 1.5 mL Lobind tubes and mixed with an equal volume of PBS buffer at pH 7.4. Plasma proteins and the

therapeutic antibody in each sample were precipitated by adding 30 μ L of methanol to the tubes. After vortexing, the samples were centrifuged for 6 minutes at 2000 rcf (relative centrifugal force) at 5°C. The supernatants were discarded and the protein pellets were resuspended in 40 μ L of 200 mM ammonium bicarbonate buffer (ABC). 5 μ L of 1M Dithiothreitol (DTT) was added to each resuspended pellet and incubated at 56°C for 30 min under gentle agitation. The samples were then cooled for 10 min at room temperature. Next, 10 μ L of internal standard working solution (100 μ g/mL) was added to each sample and mixed. The samples were further incubated with 10 μ L of Iodoacetamide (IAA) (100 mM) in 100 mM ABC buffer for 30 min under gentle rotation at room temperature while being protected from light. 30 μ g/mL of trypsin and 100 μ L of ABC buffer were added to each sample, and the samples were then incubated for 2 hours under gentle rotation at room temperature.

[0130] The digestion reactions were stopped with 30 μ L 10% formic acid (FA) and centrifuged for 10 min at 16000 rcf at 5°C. Supernatants were subjected to solid phase extraction (SPE) with OASIS MCX elution plates using a positive pressure processor manifold. Briefly, plates were equilibrated with 200 μ L of methanol and then with 200 μ L of 0.5% FA. 200 μ L of each supernatant was applied onto the plates and washed with 200 μ L 0.5% FA, 200 μ L of 0.5% FA in 80% MeOH solution, and 200 μ L of 0.5 % FA in 20% MeOH solution. Samples were finally eluted with 2x25 μ L of ammonium hydroxide buffer 5% / methanol (40:60, v/v). 10 μ L of extracts were diluted within 200 μ L of water/formic acid (100:0.5, v/v). 10 μ L of each eluted sample was used for LC-MS/MS analysis.

[0131] LC-MS/MS analysis was performed with a SCIEX triple Quadrupole API 5500 mass spectrometer running ANALYST® software version 1.6.2. The system was connected to an AGILENT 1290 INFINITY liquid chromatograph system. Chromatography was performed using a X-Bridge Protein BEH C4 column; 300Å (Waters 100 x 2.1 mm ID, 3.5 μ m particle size) at 50° and a gradient of solvent A (0.1% FA) and B (0.1% FA in acetonitrile). After equilibration for 2.5 min with solvent A, the aqueous solution was brought at 55% after 5 min with a flow rate of 600 μ L/min.

[0132] MS data were acquired in positive mode with an ion spray voltage of 5500 V, a source temperature of 600 °C, and desolvation temperature of 60°C. CE energy was optimized for each peptide (see *Table 4*).

Materials and Methods for Human Samples

[0133] Affinity Purification using ASSAYMAP® BRAVO liquid handling platform from Agilent was performed as follows: In a 96-well plate, 90 µl PBST and 10 µl of human plasma sample were added successively. The plate was vortexed 5 minutes and was put in position 4 maintained at approximately 20°C on the ASSAYMAP® BRAVO deck. The 96-well plate was filled with 20 µl of 1M Tris, and the reservoirs were filled with the following solutions in successive order: Prime and equilibrate buffer (Phosphate-buffered saline (PBST)), Cartridge Wash 1 (1 M NaCl in PBST), Cartridge Wash 2 (PBST) and elution and syringe wash buffer (1% formic acid). Next, the Affinity Purification protocol on the ASSAYMAP® BRAVO liquid handling platform was run.

[0134] Denaturation, reduction, alkylation and digestion steps are performed as follows: The 96-well plate in position 9 was centrifuged for 30 seconds. 50 µl of 0.2% RAPIGEST™ surfactant in 50 mM ammonium bicarbonate and 20 µL of 100 mM DL-Dithiothreitol in 100 mM ammonium bicarbonate were added successively. Next, the plate was centrifuged 30 seconds and incubated at approximately 56°C for 30 minutes under gentle agitation. Samples were cooled down at room temperature. 20 µL of 250 mM Iodoacetamide in 50 mM ammonium bicarbonate and 50 µl of ISW in 200 mM ammonium bicarbonate @ 0.01% TWEEN® 20 were added. The plate was centrifuged for 30 seconds and then incubated under light-protected conditions at approximately 20°C for 30 minutes under gentle agitation. 100 µL of 1 µg/µL fresh Trypsin in 50 mM ammonium bicarbonate were added and the samples were incubated at approximately 37°C overnight. Then 20 µL of 10% formic acid in water (to stop the digestion) was added.

[0135] Solid Phase Extraction using an Oasis PRIME MCX µElution plate was performed as follows: 200 µL of each supernatant was applied onto the plates and washed with 200 µL 0.5% FA and 200 µL of 0.5% FA in 80% MeOH solution. Samples were finally eluted with 50µL of ammonium hydroxide buffer 5% / methanol (40:60, v/v) and 150µL of water at 0.5% of formic acid were added into the eluted samples. The plate was loaded into auto-sampler tray maintained at +10°C and 10 µL of each sample was injected.

[0136] LC-MS/MS analysis was performed on the human plasma samples as described above for pre-clinical samples.

Table 7. Amino Acid Sequences in Example 3

SEQ ID NO.	SEQUENCE
7	TTPPVLDS DG SFFLVSK
12	EVRLVESGGG LVKPGGSLRL SCASAGFDFD NAWMTWVRQP PGKGLEWVGR ITGPGEGWSV DYAESVKGRF TISRDN TKNT LYLEMNNVRT EDTGYFFCAR TGKYYDFWSG YPPGEEYFQD WGQGT LVIVS SDKTHTQVHL TQSGPEVRKP GTSVKVSCA PGNTLKT YDL HWVRSVPGQG LQWMGWISHE GDKKVIVERF KAKVTIDWDR STNTAYLQLS GLTSGDTAVY YCAKGSKHRL RDYALYDDDG ALNWAVDVDY LSNLEFWGQG TAVTVSSDKT HTASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTPVSSSLGT QTYICNVN HK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPCR DELTKNQVSL WCLVKGFYPS DIAVEWESNG QPENNYK TTP PVLDS DGSFF LYSKLTVDKS RWQQGNVFSC SVLHEALHSH YTKSLSLSP G
13	DFVLTQSPHS LSVTPGESAS ISCKSSHS LI HGDRNNYLAW YVQKPGRSPQ LLIYLASSRA SGVPDRFSGS GSDKDFTLKI SRVETEDVGT YYCMQGRESP WTFGQGTKVD IKDKTHTASE LTQDPAVSVA LKQTVTITCR GDSLRSHYAS WYQKPGQAP VLLFYGKNR PSGIPDRFSG SASGNRASLT ITGAQAEDEA DYYCSSRDKS GSRLSVFGGG TKLTVLDKTH TRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREKV QWKVDNALQS GNSQESVTEQ DSKDSTYSL S STLTL SKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
14	QVQLVQSGGQ MKKPGESMRI SCRASGYEFI DCTLNWIRLA PGKRPEWMGW LKPRGGAVNY ARPLQGRVTM TRDVYSDTAF LELRSLTVDD TAVYFCTRGK NCDYNWDFEH WGRGTPVIVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSV VTPVSSSLGTQ TYICNVN HKP SNTKVDKKVE PKSCDKTH TC PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKT I SKAKGQPREP QVCTLPSPSRD ELTKNQVSL S CAVKGFYPSD IAVEWESNGQ PENNYK TTPP VLDS DGSFFL VSKLTVDKSR WQQGNVFSCS VLHEALHSHY TQKSLSLSPG
15	EIVLTQSPGT LSLSPGETAI ISCRTSQYGS LAWYQQRPGQ APRLVIYSGS TRAAGIPDRF SGSRWGP DYN LTISNLESGD FGVYQCQYE FFGQGTKVQV DIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC EVTHQGLSSP VT KSFNRGEC
16	LVIYSGSTR
17	DSTYSLSTL TL SK
18	DTLMISR
19	TTPPVLDS DG SFFLYSK
20	LTTPPVLDS D GSFFLVSK

Example 4: Proof of Concept Studies for using the TTPP Surrogate Peptide in a Generic Mass Spectrometry-Based Assay for Detecting and Quantifying an Exemplary Trispecific Antibody following Administration to Mice

Materials/Methods

[0137] The materials used in this Example were: trispecific antibody, serum (mouse), Protein G resin tips (Agilent), C18 resin tips (Agilent), SILU™ MAB stable isotope-labeled universal monoclonal antibody internal standard (Sigma), Heavy labeled engineered peptide internal standard (Thermo), 50mM ammonium bicarbonate, 8M urea with 550mM Tris base pH 8, 1M sodium chloride in phosphate buffered saline, 125mM dithiothreitol, 250mM iodoacetamide, phosphate buffered saline (PBS), trypsin (Promega), LysC (Promega), water, acetic acid, trifluoroacetic acid (TFA), formic acid, acetonitrile

Calibration Curve Preparation:

[0138] A calibration curve was prepared by serially diluting the trispecific antibody in mouse serum. The concentrations tested in this proof of concept study were 0.012, 0.024, 0.049, 0.098, 0.195, 0.391, 0.781, 1.563, 3.125, 6.25, 12.5, 25.0, 50.0, 100.0, 200.0, 400.0, and 800 µg/mL. Serum without trispecific antibody was used as the zero point.

Stable Isotope-Labeled Internal Standard Preparation:

[0139] On day of use, 500 µL 0.1% formic acid was added to a 100 µg vial of SILU™ MAB stable isotope-labeled universal monoclonal antibody (Sigma Aldrich) and allowed to sit at room temperature per manufacturer's instructions. Antibody concentration was 0.2µg/µL.

Heavy Labeled Engineered Peptide Internal Standard Preparation:

[0140] 2.5 mL 5% acetonitrile and with 0.1% formic acid was added to the lyophilized TTPP peptide (49 nmol) to achieve a concentration of 19.6 pmol/µL. On the day of use, the concentration of the TTPP peptide was diluted to 0.08 pmol/µL in 40% acetonitrile with 0.1% formic acid.

High throughput assay for quantification of trispecific antibody in serum using an automated liquid handling platform (Agilent BRAVO™)

Affinity Purification

[0141] For each calibration curve sample or the serum sample to be tested, 10 μL of each sample was added to separate well in a 96-well microplate. Next, 10 μL of additional mouse serum and 30 μL of 0.2 $\mu\text{g}/\mu\text{L}$ stable isotope-labeled universal monoclonal antibody internal standard was added to each well. The 96-well plate was placed on the deck of the automated liquid handling platform (Agilent BRAVO™), and an affinity purification protocol that included the steps below was run:

1. Initial syringe wash
2. Prime (100 μL PBS at 300 $\mu\text{L}/\text{min}$)
3. Equilibrate (50 μL PBS at 10 $\mu\text{L}/\text{min}$)
4. Load Sample (20 μL at 5 $\mu\text{L}/\text{min}$)
5. Cup Wash 1 (25 μL deionized water)
6. Internal Cartridge Wash 1 (50 μL 1M NaCl in PBS at 10 $\mu\text{L}/\text{min}$)
7. Cup Wash 2 (25 μL deionized water)
8. Internal Cartridge Wash 2 (50 μL PBS at 10 $\mu\text{L}/\text{min}$)
9. Stringent syringe wash (50 μL 5% acetic acid)
10. Elute (10 μL 5% acetic acid at 5 $\mu\text{L}/\text{min}$)

Digestion:

[0142] The 96-well plate containing the eluted samples was placed on the deck of the automated liquid handling platform (Agilent BRAVO™) and a digestion protocol was performed that included the steps below:

1. Transfer 40 μL 8M Urea with 550mM Tris pH 8 to each well.
2. Transfer 4.3 μL 125mM DTT to the wells and then incubate at 40°C for 60 minutes.
3. Transfer 4.7 μL 250mM IAM to the wells and then incubate at 25°C for 60 minutes.
4. Transfer 111 μL of 50mM ammonium bicarbonate to each well.
5. Transfer 20 μL of 0.5 $\mu\text{g}/\mu\text{L}$ trypsin (1:10 enzyme : substrate) and 0.2 $\mu\text{g}/\mu\text{L}$ rLysC (1:25 enzyme : substrate) to each well and incubate at 37°C for 120 minutes.
6. Transfer 20 μL of 10% TFA to each well.
7. Transfer 30 μL of 0.08 pmol/ μL heavy labeled engineered peptide (peptide internal standard) to each well.

C18 Cleanup:

[0143] The plate containing the digested samples was placed on the deck of the Agilent Bravo system and the “Peptide Cleanup” protocol was run consisting of the following steps:

1. Initial syringe wash
2. Prime (60% acetonitrile with 0.1% TFA)
3. Equilibrate (50 μ L 0.1% TFA at 25 μ L/min)
4. Load Samples (190 μ L at 5 μ L/min)
5. Cup Wash (50 μ L deionized water)
6. Internal Cartridge Wash (50 μ L 0.1% TFA at 25 μ L/min)
7. Stringent Syringe Wash (50 μ L 60% acetonitrile with 0.1% TFA)
8. Elute (20 μ L 60% acetonitrile with 0.1% TFA at 5 μ L/min)

LC-MS/MS:

[0144] Each eluted sample (20 μ L in 60% acetonitrile with 0.1% TFA) was promptly diluted to 100 μ L with a solution of 35% acetonitrile and 0.1% formic acid to achieve 40% acetonitrile and 0.1% formic acid. Each sample was transferred to an individual LC-MS vial and analyzed on an LC-MS/MS system. Retention time, parent mass, transitions, and optimized fragmentation conditions vary depending on the peptide sequence and instrument used for analysis. The TTPP peptide (TTPPVLDSDGSFFLVSK (SEQ ID NO: 7)) was analyzed on a WATERS® ACQUITY UPLC® I-Class liquid chromatography system coupled to a SCIEX QTRAP® 6500 LC-MS/MS system under the following conditions:

Column: Waters Acquity UPLC Peptide BEH C18 (2.1 x 150 mm, 1.7 μ m)

Column temperature: 30°C

Sample Injection Gradient: Begin gradient and hold at 5% B for 1 minute. Increase to 40% B in 17 minutes. Flow rate is 0.25 mL/min. Increase flow rate to 0.4 mL/min. and 90% B for blank injection.

Blank Injection Gradient: Begin gradient and hold at 90% B for 5 minutes. Flow rate is 0.4 mL/min. Decrease flow rate to 0.25 mL/min. and 5% B and hold for 3 minutes.

Mobile Phases: A is water with 0.1% formic acid; B is acetonitrile with 0.1% formic acid

Retention time: 12.9 minutes

Table 8. Mass Spectrometry Settings

	Q1 Mass	Q3 Mass	Declustering Potential	Collision Energy	Entrance Potential	Collision Cell Exit Potential
Light Peptide	905.5	804.4	64	39	10	16
Heavy Peptide	909.5	808.4	64	40	13	16

[0145] For this Example, the calibration curve samples and 6 serum samples were analyzed on 2 different days. The mice were dosed twice a week by intraperitoneal injection of trispecific antibody for a total of 7 doses. The study samples analyzed by LC-MS/MS were collected at sacrifice (approximately 30 hours after the last dose) and included a control animal dosed with saline (i.e., Mouse 6 in **FIGs 21A** and **21B**) and 5 mice dosed with 30 mg/kg of the trispecific antibody (i.e., Mice 1-5 in **FIGs 21A** and **21B**).

[0146] After LC-MS/MS, each serum calibration curve was analyzed by linear regression analysis with 1/x weighting by plotting the ratio of the TTPP peptide to its heavy labeled peptide internal standard versus the theoretical concentration. **FIGs 20A** and **20B** show the results from this analysis. Both serum curves demonstrated good linearity (with r-squared ≥ 0.99) and bias ($\leq 25\%$) for concentrations ranging from 0.012 $\mu\text{g/mL}$ to 800 $\mu\text{g/mL}$.

[0147] As shown in **FIG. 21A**, the serum samples showed higher levels of the trispecific peptide in most of the mice dosed with the trispecific antibody (#1-5) and lower levels in the saline dosed mouse (#6). The peptide levels detected in the LC-MS/MS based assay were consistent between the 2 assays (**FIG. 21A**). These samples were also analyzed using ELISA (n=4 replicates), and the results of ELISA analysis are shown in **FIG. 21B**. The relative levels of trispecific antibody detected by LC-MS/MS or ELISA show a consistent trend for all samples.

[0148] While the disclosure includes various embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations that come within the scope of the disclosure. In addition, the section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0149] All references cited in this application are expressly incorporated by reference herein.

CLAIMS

1. A method for quantitating an amount of a polypeptide comprising a portion of an antibody heavy chain constant region in a sample comprising:
 - (a) digesting the sample comprising the polypeptide comprising the portion of the antibody heavy chain constant region, wherein the portion of the antibody heavy chain constant region comprises an engineered mutation, and wherein digestion produces a peptide fragment derived from the antibody heavy chain constant region that is between 5 and 26 amino acids long and comprises the engineered mutation,
 - (b) analyzing the digested sample by mass spectrometry to determine quantity of the peptide fragment, thereby determining the quantity of the polypeptide comprising the portion of the antibody heavy chain constant region in the sample.
2. The method of claim 1, wherein the peptide fragment does not comprise a methionine (M) or cysteine (C).
3. The method of claim 1 or claim 2, wherein the peptide fragment does not comprise an asparagine (N) followed by a glycine (G) or serine (S).
4. The method of any one of claims 1-3, further comprising purifying and concentrating the digested sample prior to the mass spectrometry analysis.
5. The method of claim 4, wherein the digested sample is purified and concentrated via solid phase extraction (SPE).
6. The method of claim 4, wherein the digested sample is purified and concentrated via SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies).
7. The method of any one of claims 1-6, wherein the sample is a whole blood sample, a serum sample, a plasma sample, or a tissue sample.

8. The method of any one of claims 1-7, wherein the sample is from a mouse, a non-human primate, or a human.
9. The method of claim 8, wherein the non-human primate is a cynomolgus monkey or a rhesus monkey.
10. The method of any one of claims 1-9, wherein the sample is digested with at least one enzyme.
11. The method of claim 9, wherein the at least one enzyme is trypsin, chymotrypsin, glutamyl endopeptidase, lysyl endopeptidase, Asp-N, Arg-C, Glu-C, cyanogen bromide (CnBr), or combinations thereof.
12. The method of any one of claims 1-11, wherein the mass spectrometry is liquid chromatography-tandem mass spectrometry analysis (LC-MS/MS).
13. The method of any one of claims 1-12, wherein the polypeptide comprises a CH1 domain, and wherein the CH1 domain comprises the engineered mutation.
14. The method of any one of claims 1-12, wherein the polypeptide comprises a CH2 domain, and wherein the CH2 domain comprises the engineered mutation.
15. The method of any one of claims 1-12, wherein the polypeptide comprises a CH3 domain, and wherein the CH3 domain comprises the engineered mutation.
16. The method of claim 15, wherein the engineered mutation in the CH3 domain of the antibody heavy chain constant region is T366Y, T366W, T366S, L368A, T394W, T394S, F405A, F405W, Y407T, Y407V, or Y407A.
17. The method of claim 16, wherein the engineered mutation in the CH3 domain of the antibody heavy chain constant region is Y407V, and wherein the CH3 domain comprises an amino acid sequence set forth in SEQ ID NO: 6 (DGSFFLVLS).

18. The method of claim 17, wherein the digestion produces a peptide fragment comprising the amino acid sequence TTPPVLDSDGSFFLVSK (SEQ ID NO: 7), DGSFFLVSKLTV (SEQ ID NO: 8), or GSFFLVSKLTV (SEQ ID NO: 9).
19. The method of claim 18, wherein the sample is digested with trypsin, and wherein the digestion produces a peptide fragment consisting of the amino acid sequence TTPPVLDSDGSFFLVSK (SEQ ID NO: 7).
20. The method of claim 18, wherein the sample is digested with Asp-N, and wherein the digestion produces a peptide fragment consisting of the amino acid sequence DGSFFLVSKLTV (SEQ ID NO: 8).
21. The method of claim 18, wherein the sample is digested with Glu-C, and wherein the digestion produces a peptide fragment consisting of the amino acid sequence GSFFLVSKLTV (SEQ ID NO: 9).
22. The method of any one of claims 16-21, wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4.
23. The method of claim 15, wherein the engineered mutation in the CH3 domain of the antibody heavy chain constant region is N434S.
24. The method of claim 23, wherein the sample is digested with Glu-C and trypsin, and wherein the digestion produces a peptide fragment consisting of the amino acid sequence ALHSHYTQK (SEQ ID NO: 11).
25. The method of claim 23 or 24, wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 3.

26. The method of any one of claims 1-25, wherein the polypeptide comprising the portion of the antibody heavy chain constant region is an antibody, an Fc-fusion protein, or an immunoadhesin.
27. The method of claim 26, wherein the polypeptide comprising the portion of the antibody heavy chain constant region is an antibody.
28. The method of any one of claims 27, wherein the antibody is a therapeutic antibody.
29. The method of claim 27 or 28, wherein the antibody is a chimeric antibody, a humanized antibody, or a human antibody.
30. The method of any one of claims 27-29, wherein the antibody is a monospecific antibody, a bispecific antibody, a trispecific antibody, or a multispecific antibody.
31. The method of claim 30, wherein the antibody is a trispecific antibody.
32. The method of claim 31, wherein the trispecific antibody comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more antigen targets or target proteins, wherein a first polypeptide comprises a structure represented by the formula: V_{L2} - L_1 - V_{L1} - L_2 - CL ; the second polypeptide chain comprises a structure represented by the formula: V_{H1} - L_3 - V_{H2} - L_4 - C_{H1} -hinge- C_{H2} - C_{H3} ; the third polypeptide chain comprises a structure represented by the formula: V_{H3} - C_{H1} -hinge- C_{H2} - C_{H3} ; the fourth polypeptide chain comprises a structure represented by the formula: V_{L3} - CL , wherein V_{L1} is a first immunoglobulin light chain variable domain; V_{L2} is a second immunoglobulin light chain variable domain; V_{L3} is a third immunoglobulin light chain variable domain; V_{H1} is a first immunoglobulin heavy chain variable domain; V_{H2} is a second immunoglobulin heavy chain variable domain; V_{H3} is a third immunoglobulin heavy chain variable domain; C_L is an immunoglobulin light chain constant domain; C_{H1} is an immunoglobulin C_{H1} heavy chain constant domain; and L_1 , L_2 , L_3 and L_4 are amino acid linkers; wherein the first and second polypeptides form a cross-over light chain-heavy chain pair; and wherein the second polypeptide chain or the third polypeptide chain

comprises the amino acid sequence TTPPVLDSDGSFFLVSK (SEQ ID NO: 7), DGSFFLVSKLTV (SEQ ID NO: 8), or GSFFLVSKLTV (SEQ ID NO: 9).

33. The method of 32, wherein the first polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 12; the second polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 13; the third polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 14, and the fourth polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 15.

34. The method of any one of claims 27-33, wherein the antibody is conjugated to a drug or a label.

35. The method of claim 34, wherein the drug is selected from a chemotherapeutic agent, a cytotoxic agent, or a growth-inhibitory agent.

36. The method of claim 35, wherein the label is a radioisotope, a fluorescent dye, or an enzyme.

37. The method of any one of claims 27-36, wherein the antibody is a human IgG antibody.

38. The method of claim 37, wherein the IgG antibody is a human IgG1 antibody or a human IgG4 antibody.

39. The method of any one of claims 27-32 and 34-38, wherein the antibody binds A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H4/VTCN1, B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1b, CCL5/RANTES, CCL7/MCP-3, CCL8/mcp-2, CCL11/eotaxin, CCL15/MIP-1d, CCL17/TARC, CCL19/MIP-3b, CCL20/MIP-3a, CCL21/MIP-2, CCL24/MPIF-2/eotaxin-2, CCL25/TECK, CCL26/eotaxin-3, CCR3, CCR4, CD3, CD19, CD20, CD23/FCER2, CD24, CD27, CD28, CD38, CD39, CD40, CD70, CD80/ B7-1, CD86/B7-2, CD122, CD137/41BB, CD137L, CD152/CTLA4, CD154/CD40L, CD160, CD272, CD273/ PDL2, CD274/PDL1, CD275/B7H2, CD276/B7H3, CD278/ ICOS, CD279/PD-1, CDH1/E-cadherin, chitinase, CLEC9, CLEC91,

CRTH2, CSF-1/M-CSF, CSF-2/GM-CSF, CSF-3/G-CSF, CX3CL1/SCYD1, CXCL12/SDF1, CXCL13, CXCR3, DNGR-1, ectonucleoside triphosphate diphosphohydrolase 1, EGFR, ENTPD1, FCER1A, FCER1, FLAP, FOLH1, Gi24, GITR, GITRL, GM-CSF, Her2, HHLA2, HMGB1, HVEM, ICOSLG, IDO, IFN α , IgE, IGF1R, IL2Rbeta, IL1, IL1A, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL10, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb/IL25, IL18, IL22, IL23, IL25, IL27, IL33, IL35, ITGB4/b4 integrin, ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, NCR3LG1, NKG2D, NTPDase-1, OX40, OX40L, PD-1H, platelet receptor, PROM1, S152, SIS1P, SLC, SPG64, ST2/receptor for IL33, STEAP2, Syk kinase, TACI, TDO, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP/ IL7Ra, TSLPR, TWEAK, VEGF, VISTA, Vstm3, WUCAM, or XCR/GPR5/CCXCR1.

40. The method of any one of claims 1-39, wherein the method is for use in pharmacokinetic study of the polypeptide comprising an antibody heavy chain constant region in a mouse, a non-human primate, and a human.